WO1999065940A1 - Proteines anti-angiogeniques et methodes d'utilisation de ces proteines - Google Patents

Proteines anti-angiogeniques et methodes d'utilisation de ces proteines Download PDF

Info

Publication number
WO1999065940A1
WO1999065940A1 PCT/US1999/013737 US9913737W WO9965940A1 WO 1999065940 A1 WO1999065940 A1 WO 1999065940A1 US 9913737 W US9913737 W US 9913737W WO 9965940 A1 WO9965940 A1 WO 9965940A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
cells
angiogenic
fragment
tumstatin
Prior art date
Application number
PCT/US1999/013737
Other languages
English (en)
Inventor
Raghuram Kalluri
Original Assignee
Beth Israel Deaconess Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Center filed Critical Beth Israel Deaconess Medical Center
Priority to IL14023999A priority Critical patent/IL140239A0/xx
Priority to EP99928762A priority patent/EP1086129A1/fr
Priority to JP2000554765A priority patent/JP2002517999A/ja
Priority to CA002331332A priority patent/CA2331332A1/fr
Priority to AU45755/99A priority patent/AU753249B2/en
Publication of WO1999065940A1 publication Critical patent/WO1999065940A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • Vascular basement membranes are composed of macromolecules such as collagen, laminin, heparan sulfate proteoglycans, fibronectin and entactin (Timpl, R., 1996, Curr Opin Cell Biol 8:618-24). Functionally, collagen promotes cell adhesion, migration, differentiation and growth (Paulsson, M., 1992, Crit. Rev. Biochem. Mol. Biol. 27:93-127), and via these functions is presumed to play a crucial role in endothelial cell proliferation and behavior during angiogenesis, which is the process of formation of new blood vessels from pre-existing ones (Madri, J. A. et al, 1986, J. Histochem. Cytochem.
  • Angiogenesis is a complex process, and requires sprouting and migration of endothelial cells, proliferation of those cells, and their differentiation into tube-like structures and the production of a basement membrane matrix around the developing blood vessel. Additionally angiogenesis is a process critical for normal physiological events such as wound repair and endometrium remodeling
  • the present invention relates to proteins comprising the NCI domain of an alpha chain of Type IV collagen having anti-angiogenic properties.
  • the present invention relates to the novel proteins Arresten, Canstatin and Tumstatin, and to biologically active (e.g., anti-angiogenic) fragments, mutants, analogs, homologs and derivatives thereof, as well as multimers (e.g., dimers) and fusion proteins (also referred to herein as chimeric proteins) thereof.
  • biologically active e.g., anti-angiogenic fragments, mutants, analogs, homologs and derivatives thereof, as well as multimers (e.g., dimers) and fusion proteins (also referred to herein as chimeric proteins) thereof.
  • These proteins all comprise the C-terminal fragment of the NCI (non-collagenous 1) domain of Type IN collagen.
  • Arresten, Canstatin and Tumstatin are each a C-terminal fragment of the NCI domain of the ⁇ l chain, ⁇ 2 chain and ⁇ 3 chain, respectively, of Type IN collagen.
  • Arresten, Canstatin and Tumstatin are monomeric proteins. All three arrest tumor growth in vivo, and also inhibit the formation of capillaries in several in vitro models, including the endothelial tube assay.
  • the present invention encompasses isolated and recombinantly-produced Arresten, also referred to herein as "Arrestin,” which comprises the ⁇ C1 domain of the ⁇ l chain of Type IV collagen, having anti-angiogenic activity, anti-angiogenic fragments of the isolated Arresten, multimers of the isolated Arresten and anti- angiogenic fragments, and polynucleotides encoding those anti-angiogenic proteins. Also encompassed are compositions comprising isolated Arresten, its anti- angiogenic fragments, or both, as biologically active components.
  • the invention features a method of treating a proliferative disease such as cancer, in a mammal where said disease is characterized by angiogenic activity, the method comprising administering to the mammal a composition containing anti- angiogenic Arresten or its fragments.
  • a composition containing anti- angiogenic Arresten or its fragments can also be used to prevent cell migration or endothelial cell proliferation.
  • antibodies to the isolated anti-angiogenic Arresten and its fragments are also featured.
  • the present invention also encompasses isolated and recombinantly produced Canstatin, which comprises the NCI domain of the ⁇ 2 chain of Type IV collagen, having anti-angiogenic activity, anti-angiogenic fragments of the isolated Canstatin, multimers of the isolated Canstatin and anti-angiogenic fragments, and polynucleotides encoding those anti-angiogenic proteins. Also encompassed are compositions comprising isolated Canstatin, its anti-angiogenic fragments, or both, as biologically active ingredients.
  • the invention features a method of treating a proliferative disease such as cancer, in a mammal, where said disease is characterized by angiogenic activity, the method comprising administering to the mammal a composition containing anti-angiogenic Canstatin or its fragments.
  • the anti-angiogenic Canstatin and its fragments can also be used to prevent cell migration or endothelial cell proliferation.
  • antibodies to the isolated anti-angiogenic Canstatin and its fragments are also be used to prevent cell migration or endothelial cell proliferation.
  • the invention likewise encompasses isolated and recombinantly-produced Tumstatin, comprising the NCI domain of the ⁇ 3 chain of Type IV collagen, having anti-angiogenic activity, anti-angiogenic fragments of the isolated Tumstatin, multimers of the isolated Tumstatin and anti-angiogenic fragments, and polynucleotides encoding those anti-angiogenic proteins. Also encompassed are compositions comprising isolated Tumstatin, its anti-angiogenic fragments, or both, as biologically active ingredients.
  • the invention features a method of treating a proliferative disease such as cancer in a mammal, where said disease is characterized by angiogenic activity, the method comprising administering to the mammal a composition containing anti-angiogenic Tumstatin or its fragments.
  • the anti-angiogenic Tumstatin and its fragments can also be used to prevent cell migration or endothelial cell proliferation.
  • antibodies to the isolated anti-angiogenic Tumstatin and its fragments are also be used to prevent cell migration or endothelial cell proliferation.
  • Figs. 1 A and IB are diagrams depicting the nucleotide (Fig. 1 A, SEQ LD NO:l) and amino acid (Fig. IB, SEQ ID NO:2) sequences of the ⁇ l chain of human Type IV collagen. The locations of the forward (SEQ ID NO:3) and reverse (SEQ ID NO:4) primers are indicated.
  • Fig. 2 is a schematic diagram representing the Arresten cloning vector pET22b(+). Forward (SEQ ID NO:3) and reverse (SEQ ID NO:4) primers and site into which Arresten was cloned are indicated.
  • Figs. 3 A and 3B are a pair of line graphs showing the effects of Arresten (Fig. 3 A, 0 ⁇ g/ml to 10 ⁇ g/ml, x-axis) and endostatin (Fig. 3B, 0 ⁇ g/ml to 10 ⁇ g/ml, x-axis) on 3 H-thymidine incorporation (y-axis) as an indicator of endothelial cell (C- PAE) proliferation.
  • Figs. 4A, 4B, 4C and 4D are a set of four bar charts showing the effect of Arresten and endostatin on 3 H-thymidine incorporation (y-axis) as an indicator of endothelial cell proliferation.
  • Figs. 4A, 4B and 4C show the effect of Arresten (0 ⁇ g/ml - 50 ⁇ g/ml (Figs. 4A and 4B) and 0 ⁇ g/ml - 10 ⁇ g/ml (Fig. 4C)) on 786-0, PC-3, HPEC cells respectively.
  • Fig. 4D shows the effect of 0.1 - 10 ⁇ g/ml endostatin on A-498 cells.
  • Figs. 5 A, 5B and 5 C are a set of four photomicrographs showing the effects of Arresten (2 ⁇ g/ml, Fig. 5B) and endostatin (20 ⁇ g/ml, Fig. 5C) on endothelial cell migration via FBS-induced chemotaxis in human umbilical endothelial (ECV-304) cells.
  • Fig. 5A shows untreated control cells.
  • Fig. 6 is a bar chart showing in graphic form the results of Fig. 5.
  • Fig. 6 shows the effect of either Arresten (2 ⁇ g/ml or 20 ⁇ g/ml) and endostatin (2.5 ⁇ g/ml and 20 ⁇ g/ml) on the migration of ECV-304 endothelial cells.
  • Fig. 7 is a line graph showing the effect of Arresten on the endothelial tube formation. Percent tube formation is shown on the y-axis, and concentration of inhibitor on the x-axis. The treatments were: none (control, ⁇ ), BSA (control, ⁇ ), 7S domain (control, X) and Arresten ( ⁇ ).
  • Figs. 8 A and 8B are a pair of photomicrographs showing the effect of Arresten (0.8 ⁇ g/ml, Fig. 8B) on endothelial tube formation relative to control (Fig. 8A).
  • Figs. 9A, 9B, 9C and 9D are a set of four line graphs showing the effect of Arresten and endostatin on tumor growth in vivo.
  • Fig. 9A is a plot showing the increase in tumor volume from 700 mm 3 for 10 mg/kg Arresten-treated (D), BSA- treated (+), and control mice (•).
  • Fig. 9B shows the increase in tumor volume from 100 mm 3 for 10 mg/kg Arresten-treated (D) and BSA-treated (+) tumors.
  • Fig. 9C shows the increase in tumor volume from about 100 mm for 10 mg/kg Arresten- treated (D), Endostatin-treated (A), and control mice (•).
  • Fig. 9D shows the increase for 200 mm 3 tumors when treated with Arresten (D) versus controls (•).
  • Fig. 10A and 10B are diagrams depicting the nucleotide (Fig. 10 A, SEQ LD NO:5) and amino acid (Fig. 10B, SEQ ID NO:6) sequences of the ⁇ 2 chain of human Type IN collagen. The locations of the forward (SEQ ID ⁇ O:7) and reverse (SEQ LD NO:8) primers are indicated.
  • Fig. 11 is a schematic diagram representing the Canstatin cloning vector pET22b(+). Forward (SEQ LD NO:7) and reverse (SEQ D NO:8) primers and site into which Canstatin was cloned are indicated.
  • Figs. 12 A, 12B, 12C and 12D are histograms showing the effect of varying concentrations of Canstatin (x-axis) on proliferation of endothelial (C-PAE) cells (Figs. 12A and 12C) and non-endothelial (786-0, PC-3 and HEK 293) cells (Figs. 12B and 12D). Proliferation was measured as a function of 3 H-thymidine incorporation (Figs. 12A and 12B) and methylene blue staining (Figs. 12B and 12D). Fig.
  • FIG. 13 is a bar chart showing the number of migrated endothelial cells per field (y-axis) for treatments of no VEGF (no VEGF or serum), and VEGF (1% FCS and 10 ng/ml VEGF) cells, and for treatments of 0.01 Canstatin (1% FCS and 10 ng/ml VEGF and 0.01 ⁇ g/ml Canstatin) and 1.0 ⁇ g/ml Canstatin (1% FCS and 10 ng/ml VEGF and 1 ⁇ g/ml Canstatin).
  • FIG. 14 is a line graph showing the amount of endothelial tube formation as a percent of control (PBS-treated wells) tube formation (y-axis) under varying treatments of BSA (D), Canstatin ( ⁇ ), and ⁇ 5NCl (O). Vertical bars represent the standard error of the mean.
  • Figs. 15 A, 15B, 15C and 15D are line graphs depicting the effect on PC-3 cells (Figs. 15A and 15B) and 786-0 cells (Figs. 15C and 15D) of Canstatin ( ⁇ ), endostatin (O) and controls (D) on fractional tumor volume (y-axis, Figs. 15A and
  • FIG. 16A and 16B are diagrams depicting the nucleotide (Fig. 16A, SEQ LD
  • Fig. 17 is a schematic diagram representing the Tumstatin cloning vector pET22b(+). Forward (SEQ ID NO:l 1) and reverse (SEQ ID NO:12) primers and site into which Tumstatin was cloned are indicated.
  • Fig. 18 is a schematic diagram showing the location of truncated amino acids within the ⁇ 3(IN)NCl monomer in the Tumstatin mutant Tumsatin N-53.
  • the filled circles correspond to the N-terminal 53 amino acid residues deleted from Tumstatin to generate this mutant.
  • the disulfide bonds, marked by short bars, are arranged as they occur in ⁇ l(IN)NCl and ⁇ 2(IV)NCl.
  • Figs. 19 A, 19B and 19C are a set of three histograms showing 3 H-thymidine incorporation (y-axis) for C-PAE cells (Fig. 19A), PC-3 cells (Fig. 19B) and 786-0 cells (Fig. 19C) when treated with varying concentrations of Tumstatin (x-axis). All groups represent triplicate samples.
  • Fig. 20 is a line graph showing the effect on endothelial tube formation (y- axis) of varying amounts (x-axis) of Tumstatin (•), BSA (control, D) and 7S domain (control, O).
  • Figs. 21 A and 2 IB are a pair of line graphs showing the effects on tumor volume (mm 3 , y-axis) against days of treatment (x-axis) of Tumstatin (•) and endostatin (O) versus controls (D). Data points marked with an asterisk are significant, with P ⁇ 0.05 by one-tailed Student's test.
  • Fig. 20 is a line graph showing the effect on endothelial tube formation (y- axis) of varying amounts (x-axis) of Tumstatin (•), BSA (control, D) and 7S domain (control, O).
  • Figs. 21 A and 2 IB are a pair of line graphs showing the effects on tumor volume (mm 3 , y-axis
  • FIG. 22 is a graph showing increase in tumor volume (y-axis) against day of treatment (x-axis) for control mice (D) and mice treated with the Tumstatin mutant N-53 (•). Data points marked with an asterisk are significant, with P ⁇ 0.05 by one- tailed Student's test.
  • Fig. 23 is a line graph showing the inhibition of endothelial tube formation (y-axis) by varying concentrations (x-axis) of Arresten (•), Canstatin (O), the 12 kDa Arresten fragment ( ⁇ ), the 8 kDa Arresten fragment (D), and the 10 kDa Canstatin fragment (A).
  • Fig. 24 is a line graph showing the inhibition of endothelial tube formation (y-axis) by varying concentrations (x-axis) of Tumstatin fragment 333 (•), Tumstatin fragment 334 (O), BSA (control, ⁇ ), ⁇ 6 (control, D), and Tumstatin (A).
  • Type IV collagen is composed of six distinct gene products, namely, ⁇ l through ⁇ 6 (Prockop, D. J.
  • Vascular endothelial growth factor VEGF
  • bFGF basic fibroblast growth factor
  • VEGF vascular endothelial growth factor
  • bFGF basic fibroblast growth factor
  • angiogenesis inhibitors have been recently identified, and certain factors such as LFN-a, platelet- factor-4 (Maione, T.E. et al, 1990, Science 247:77-9) and PEX (Brooks, P.C.
  • proteins, and fragments, analogs, derivatives, homologs and mutants thereof with anti-angiogenic properties are described, along with methods of use of these proteins, analogs, derivatives, homologs and mutants to inhibit angiogenesis-mediated poliferative diseases.
  • the proteins comprise the NCI domain of the ⁇ chain of Type FV collagen, or portions of the domain, and specifically comprise monomers of the NCI domain of the ⁇ l, ⁇ 2 and ⁇ 3 chains of Type IN collagen. These proteins, especially when in monomeric form, arrest tumor growth in in vivo models of cancer, and also inhibit the formation of capillaries in several in vitro models, including the endothelial tube assay. These proteins may also include the junction region of the ⁇ C1 domain.
  • the ⁇ l, ⁇ 2, or ⁇ 3 chains are preferred, as evidence suggests that the ⁇ 4, ⁇ 5, and ⁇ 6 chains have reduced or non-detectable anti-angiogenic activity.
  • monomeric forms of the proteins are preferred, as evidence suggests that the hexameric forms also have little or reduced activity. More particularly, the present invention describes a protein designated
  • human Arresten can be produced in E. coli using a bacterial expression plasmid, such as p ⁇ T22b, which is capable of periplasmic transport, thus resulting in soluble protein.
  • the protein is expressed as a 29 kDa fusion protein with a C-terminal six-histidine tag.
  • the additional 3 kDa (beyond 26 kDa) arises from polylinker and histidine tag sequences.
  • Arresten was also produced as a secreted soluble protein in 293 kidney cells using the pcD ⁇ A 3.1 eukaryotic vector. This 293-produced protein has no purification or detection tags.
  • c ⁇ /z-produced Arresten inhibits proliferation of bFGF-stimulated endothelial cells in a dose-dependent manner, with an ED 50 of 0.25 ⁇ g/ml. No significant effect was observed on proliferation of renal carcinoma cells (786-0), prostate cancer cells (PC-3), or human prostate epithelial cells (HPEC). Endostatin inhibited proliferation of C-PAE cells at an ED 50 of 0.75 ⁇ g/ml, 3-fold higher than Arresten, and did not inhibit A-498 cancer cells.
  • Canstatin the NCI domain of the ⁇ 2 chain of Type IN collagen was used to inhibit angiogenesis, as assayed by inhibition of the proliferation and migration of endothelial cells, and by inhibition of endothelial tube formation.
  • the specific inhibition of endothelial cell proliferation and migration by Canstatin also demonstrate its anti-angiogenic activity, and that it may function via a cell surface protein receptor.
  • Integrins are potential candidate molecules based on their extracellular matrix binding capacity and ability to modulate cell behavior such as migration and proliferation.
  • avb3 integrin is a possible canstatin receptor, due to its induction during angiogenesis, and its promiscuous binding capacity.
  • Tumstatin the ⁇ C1 domain of the ⁇ 3 chain of type IN collagen (Timpl, R. et al, 1981, Eur. J. Biochem. 120:203-11; Turner, ⁇ . et al, 1992, J. Clin. Invest. 89:592-601)
  • the distribution of the ⁇ 3 (IN) chain is limited to certain basement membranes, such as GBM, several basement membranes of the cochlea, ocular basement membrane such as anterior lens capsule, Descemet's membrane, ovarian and testicular basement membrane (Frojdman, K.
  • ⁇ 3 (IN) chain is not the original component in the skin of normal humans, the process of collagen assembly and angiogenesis in the lesion of wound healing may not be altered by the treatment using tumstatin.
  • the ⁇ 3 (IN) chain is expressed in human kidney vascular basement membrane as well as GBM (Kalluri, R. et al, 1997, J. Clin. Invest. 99:2470-8). These 'pre-existing' vessels are speculated to be involved in the progression of primary renal tumors such as renal cell carcinoma.
  • Tumstatin can be effective in the treatment of primary renal tumors by disrupting neovascularization mediated by the assembly of the ⁇ 3 (IN) chain with the other ⁇ -chains.
  • tumstatin in inhibiting renal cell carcinoma growth in vivo demonstrates this molecule's potential as an effective anti-angiogenic therapy against this tumor type.
  • Tumstatin specifically inhibited endothelial cell proliferation and had no effect on the proliferation of tumor cell lines PC-3, and 786- O in vitro.
  • tumstatin did not inhibit endothelial cell migration, it significantly suppressed endothelial tube formation in vitro.
  • tumstatin inhibited angiogenesis in the matrigel plug assay and suppressed the growth of PC-3 tumor and 786-O tumors in mouse xenograft model.
  • the fact that tumstatin inhibited the growth of large tumors is encouraging, especially considering the treatment of tumors in the clinical setting.
  • tumstatin possesses the pathogenic epitope for Goodpasture syndrome, an autoimmune disease characterized by pulmonary hemorrhage and rapidly progressive glomerulonephritis (Butkowski, RJ. et al. 1987, J. Biol. Chem. 262:7874-77; Saus, J. et al, 1988, J. Biol. Chem.
  • Truncated tumstatin was synthesized, lacking the ⁇ -terminal 53 amino acid residues in order to remove the epitope for Goodpasture syndrome, and this molecule exhibit inhibitory effect on 786-O tumor growth in mouse xenograft model. Additionally, this molecule did not bind autoantibodies from severe patients with Goodpasture syndrome. These results show that the anti-angiogenic region of tumstatin is conserved even when the ⁇ - terminal 53 amino acids are removed.
  • endothelial cell proliferation by tumstatin strongly suggests that it may function via a cell surface protein/receptor.
  • Angiogenesis also depends on specific endothelial cell adhesive events mediated by integrin avb3 (Brooks, P.C. et al, 1994, Cell 79:1157-64). Tumstatin may disrupt the interaction of proliferating endothelial cells to the matrix component, and thus drive endothelial cells to undergo apoptosis (Re, F. et al, 1994, J. Cell. Biol. 127:537-46).
  • MMP Matrix Metalloproteinases
  • PX an inhibitor of MMP-2
  • Tumstatin may function through inhibiting the activity of MMPs. Tumstatin inhibits angiogenesis in vitro and in vivo, resulting in the suppression of tumor progression. In order to apply this strategy to patients, its potential toxicity or side effects by systemic administration must also be considered.
  • the distribution of the ⁇ 3 (IV) chain is limited to basement membranes of selected organs, and so tumstatin is likely to be less harmful considering the possible mechanism of this molecule by inhibiting the assembly of ⁇ -chains. Furthermore the ⁇ 3 (IV) chain is observed in the vascular basement membrane of the kidney
  • angiogenesis means the generation of new blood vessels into a tissue or organ, and involves endothelial cell proliferation. Under normal physiological conditions, humans or animals undergo angiogenesis only in very specific restricted situations. For example, angiogenesis is normally observed in wound healing, fetal and embryonal development, and formation of the corpus luteum, endometriurn and placenta.
  • Endothelium means a thin layer of flat epithelial cells that lines serous cavities, lymph vessels, and blood vessels.
  • Anti-angiogenic activity therefore refers to the capability of a composition to inhibit the growth of blood vessels.
  • the growth of blood vessels is a complex series of events, and includes localized breakdown of the basement membrane lying under the individual endothelial cells, proliferation of those cells, migration of the cells to the location of the future blood vessel, reorganization of the cells to form a new vessel membrane, cessation of endothelial cell proliferation, and, incorporation of pericytes and other cells that support the new blood vessel wall.
  • Anti-angiogenic activity as used herein therefore includes interruption of any or all of these stages, with the end result that formation of new blood vessels is inhibited.
  • Anti-angiogenic activity may include endothelial inhibiting activity, which refers to the capability of a composition to inhibit angiogenesis in general and, for example, to inhibit the growth or migration of bovine capillary endothelial cells in culture in the presence of fibroblast growth factor, angiogenesis-associated factors, or other known growth factors.
  • a "growth factor” is a composition that stimulates the growth, reproduction, or synthetic activity of cells.
  • An "angiogenesis-associated factor” is a factor which either inhibits or promotes angiogenesis.
  • An example of an angiogenesis-associated factor is an angiogenic growth factor, such as basic fibroblastic growth factor (bFGF), which is an angiogenesis promoter.
  • bFGF basic fibroblastic growth factor
  • angiogenesis-associated factor is an angiogenesis inhibiting factor such as e.g., angiostatin (see, e.g., U.S. Pat. No. 5,801,012, U.S. Pat. No. 5,837,682, U.S. Pat. No. 5,733,876, U.S. Pat. No. 5,776,704, U.S. Pat. No. 5,639,725, U.S. Pat. No. 5,792,845, WO 96/35774, WO 95/29242, WO 96/41194, WO 97/23500) or endostatin (see, e.g., WO 97/15666).
  • angiostatin see, e.g., U.S. Pat. No. 5,801,012, U.S. Pat. No. 5,837,682, U.S. Pat. No. 5,733,876, U.S. Pat. No. 5,776,704, U.S. Pat. No. 5,639,725, U.S. Pat.
  • compositions have anti-angiogenic activity, and behaves similarly as do Arresten, Canstatin and Tumstatin, as determined in standard assays.
  • Standard assays include, but are not limited to, those protocols used in the molecular biological arts to assess anti-angiogenic activity, cell cycle arrest, and apoptosis.
  • Such assays include, but are not limited to, assays of endothelial cell proliferation, endothelial cell migration, cell cycle analysis, and endothelial cell tube formation, detection of apoptosis, e.g., by apoptotic cell morphology or Annexin V-FITC assay, chorioallantoic membrane (CAM) assay, and inhibition of renal cancer tumor growth in nude mice.
  • assays include, but are not limited to, assays of endothelial cell proliferation, endothelial cell migration, cell cycle analysis, and endothelial cell tube formation, detection of apoptosis, e.g., by apoptotic cell morphology or Annexin V-FITC assay, chorioallantoic membrane (CAM) assay, and inhibition of renal cancer tumor growth in nude mice.
  • apoptosis e.g., by apoptotic cell morphology or Annexin V-FITC assay
  • Arrow also referred to herein as “Arrestin,” is intended to include fragments, mutants, homologs, analogs, and allelic variants of the amino acid sequence of the Arresten sequence, as well as Arresten from other mammals, and fragments, mutants, homologs, analogs and allelic variants of the Arresten amino acid sequence.
  • Canstatin is intended to include fragments, mutants, homologs, analogs, and allelic variants of the amino acid sequence of the Canstatin sequence, as well as Canstatin from other mammals, and fragments, mutants, homologs, analogs and allelic variants of the Canstatin amino acid sequence.
  • Tustatin is intended to include fragments, mutants, homologs, analogs, and allelic variants of the amino acid sequence of the Tumstatin sequence, as well as Tumstatin from other mammals, and fragments, mutants, homologs, analogs and allelic variants of the Tumstatin amino acid sequence.
  • the present invention is contemplated to include any derivatives of Arresten, Canstatin or Tumstatin that have endothelial inhibitory activity (e.g., the capability of a composition to inhibit angiogenesis in general and, for example, to inhibit the growth or migration of bovine capillary endothelial cells in culture in the presence of fibrobjast growth factor, angiogenesis-associated factors, or other known growth factors).
  • the present invention includes the entire Arresten, Canstatin or Tumstatin protein, derivatives of these proteins and biologically-active fragments of these proteins. These include proteins with Arresten, Canstatin or Tumstatin activity that have amino acid substitutions or have sugars or other molecules attached to amino acid functional groups.
  • the invention also describes fragments, mutants, homologs and analogs of Arresten, Canstatin and Tumstatin.
  • a "fragment" of Arresten, Canstatin or Tumstatin is any amino acid sequence shorter that the Arresten, Canstatin or Tumstatin molecule, comprising at least 25 consecutive amino acids of the Arresten, Canstatin or Tumstatin polypeptide.
  • Such molecules may or may not also comprise additional amino acids derived from the process of cloning, e.g., amino acid residues or amino acid sequences corresponding to full or partial linker sequences.
  • such mutants, with or without such additional amino acid residues must have substantially the same biological activity as the natural or full-length version of the reference polypeptide.
  • Tumstatin N-53 One such fragment, designated “Tumstatin N-53”, was found to have anti- angiogenic activity equivalent to that of full-length Tumstatin, as determined by standard assays.
  • Tumstatin N-53 comprises a Tumstatin molecule wherein the N- terminal 53 amino acids have been deleted.
  • Other mutant fragments described herein have been found to have very high levels of anti-angiogenic activity, as shown by the assays described herein.
  • Tumstatin 333 comprises amino acids 2 to 125 of SEQ ID NO: 10
  • Tumstatin 334 comprises amino acids 126 to 245 of SEQ LD NO: 10.
  • mutant of Arresten, Canstatin or Tumstatin is meant a polypeptide that includes any change in the amino acid sequence relative to the amino acid sequence of the equivalent reference Arresten, Canstatin or Tumstatin polypeptide. Such changes can arise either spontaneously or by manipulations by man, by chemical energy (e.g. , X-ray), or by other forms of chemical mutagenesis, or by genetic engineering, or as a result of mating or other forms of exchange of genetic information. Mutations include, e.g., base changes, deletions, insertions, inversions, translocations, or duplications.
  • Mutant forms of Arresten, Canstatin or Tumstatin may display either increased or decreased anti-angiogenic activity relative to the equivalent reference Arresten, Canstatin or Tumstatin polynucleotide, and such mutants may or may not also comprise additional amino acids derived from the process of cloning, e.g., amino acid residues or amino acid sequences corresponding to full or partial linker sequences.
  • Mutants/fragments of the anti-angiogenic proteins of the present invention can be generated by PCR cloning.
  • the fragments designated “Tumstatin 333" and “Tumstatin 334" were generated in this way, and have anti-angiogenic activity superior to that of full-length Tumstatin, as is described in Example 18, below, and shown in Figs. 23 and 24.
  • PCR primers are designed from known sequence in such a way that each set of primers will amplify known subsequence from the overall protein. These subsequences are then cloned into an appropriate expression vector, such as the pET22b vector, and the expressed protein tested for its anti-angiogenic activity as described in the assays below.
  • Mutants/fragments of the anti-angiogenic proteins of the present invention can also be generated by Pseudomonas elastase digestion, as described by Mariyama, M. et al (1992, J. Biol. Chem. 267:1253-8), and in Example 24, below. This method was used to produce the 12 kDa and 8 kDa Arrestin mutants, and the 10 kDa Canstatin mutant, all three of which have higher levels of anti-angiogenic activity than the original full-length proteins.
  • analog of Arresten, Canstatin or Tumstatin is meant a non-natural molecule substantially similar to either the entire Arresten, Canstatin or Tumstatin molecule or a fragment or allelic variant thereof, and having substantially the same or superior biological activity.
  • Such analogs are intended to include derivatives (e.g., chemical derivatives, as defined above) of the biologically active Arresten, Canstatin or Tumstatin, as well as its fragments, mutants, homologs, and allelic variants, which derivatives exhibit a qualitatively similar agonist or antagonist effect to that of the unmodified Arresten, Canstatin or Tumstatin polypeptide, fragment, mutant, homolog, or allelic variant.
  • allele of Arresten, Canstatin or Tumstatin is meant a polypeptide sequence containing a naturally-occurring sequence variation relative to the polypeptide sequence of the reference Arresten, Canstatin or Tumstatin polypeptide.
  • allele of a polynucleotide encoding the Arresten, Canstatin or Tumstatin polypeptide is meant a polynucleotide containing a sequence variation relative to the reference polynucleotide sequence encoding the reference Arresten, Canstatin and Tumstatin polypeptide, where the allele of the polynucleotide encoding the Arresten, Canstatin or Tumstatin polypeptide encodes an allelic form of the Arresten, Canstatin or Tumstatin polypeptide.
  • a given polypeptide may be either a fragment, a mutant, an analog, or allelic variant of Arresten, Canstatin or Tumstatin, or it may be two or more of those things, e.g., a polypeptide may be both an analog and a mutant of the Arresten, Canstatin or Tumstatin polypeptide.
  • a shortened version of the Arresten, Canstatin or Tumstatin molecule e.g., a fragment of Arresten, Canstatin or Tumstatin
  • a molecule is created that is both a fragment and a mutant of Arresten, Canstatin or Tumstatin.
  • a mutant may be created, which is later discovered to exist as an allelic form of Arresten, Canstatin or Tumstatin in some mammalian individuals.
  • Such a mutant Arresten, Canstatin or Tumstatin molecule would therefore be both a mutant and an allelic variant.
  • Such combinations of fragments, mutants, allelic variants, and analogs are intended to be encompassed in the present invention.
  • the Tumstatin made by the E coli expression cloning method described in Example 18, below is a monomer. It is also a fusion or chimeric protein because the E. coli expression cloning method adds polylinker sequence and a histidine tag to the expressed protein that do not exist in the native protein.
  • Tumstatin N-53 also described in Example 18, is a fragment and a deletion mutant of the full-length Tumstatin protein, and when made by the same E. coli expression cloning method, also has additional sequences added to it, and is therefore a fusion or chimeric mutant fragment of the full-length Tumstatin protein. Subunits of this Tumstatin N-53, when combined together, e.g., into a dimer, trimer, etc., would produce a multimeric fusion of chimeric mutant fragment of the Tumstatin protein.
  • proteins that have substantially the same amino acid sequence as Arresten, Canstatin or Tumstatin or polynucleotides that have substantially the same nucleic acid sequence as the polynucleotides encoding Arresten, Canstatin or Tumstatin.
  • substantially the same sequence means a nucleic acid or polypeptide that exhibits at least about 70 % sequence identity with a reference sequence, e.g., another nucleic acid or polypeptide, typically at least about 80% sequence identity with the reference sequence, preferably at least about 90% sequence identity, more preferably at least about 95% identity, and most preferably at least about 97% sequence identity with the reference sequence.
  • polypeptide indicates a molecular chain of amino acids and does not refer to a specific length of the product. Thus, peptides, oligopeptides and proteins are included within the definition of polypeptide. This term is also intended to include polypeptide that have been subjected to post-expression modifications such as, for example, glycosylations, acetylations, phosphorylations and the like.
  • Sequence identity refers to the subunit sequence similarity between two polymeric molecules, e.g. , two polynucleotides or two polypeptides . When a subunit position in both of the two molecules is occupied by the same monomeric subunit, e.g., if a position in each of two peptides is occupied by serine, then they are identical at that position.
  • the identity between two sequences is a direct function of the number of matching or identical positions, e.g., if half (e.g., 5 positions in a polymer 10 subunits in length), of the positions in two peptide or compound sequences are identical, then the two sequences are 50% identical; if 90% of the positions, e.g., 9 of 10 are matched, the two sequences share 90% sequence identity.
  • amino acid sequences R 2 R 5 R 7 R 10 R 6 R 3 and RgRgRjR K j gRs have 3 of 6 positions in common, and therefore share 50% sequence identity
  • sequences R 2 R 5 R 7 R I0 R 6 R 3 and RgR j R j nR ⁇ have 3 of 5 positions in common, and therefore share 60% sequence identity.
  • the identity between two sequences is a direct function of the number of matching or identical positions.
  • sequence homology it is meant that the two sequences differ from each other only by conservative substitutions.
  • conservative substitutions consist of substitution of one amino acid at a given position in the sequence for another amino acid of the same class (e.g., amino acids that share characteristics of hydrophobicity, charge, pK or other conformational or chemical properties, e.g., valine for leucine, arginine for lysine), or by one or more non-conservative amino acid substitutions, deletions, or insertions, located at positions of the sequence that do not alter the conformation or folding of the polypeptide to the extent that the biological activity of the polypeptide is destroyed.
  • “conservative substitutions” include substitution of one non-polar (hydrophobic) residue such as isoleucine, valine, leucine or methionine for another; the substitution of one polar (hydrophilic) residue for another such as between arginine and lysine, between glutamine and asparagine, between threonine and serine; the substitution of one basic residue such as lysine, arginine or histidine for another; or the substitution of one acidic residue, such as aspartic acid or glutamic acid for another; or the use of a chemically derivatized residue in place of a non-derivatized residue; provided that the polypeptide displays the requisite biological activity.
  • Two sequences which share sequence homology may called “sequence homologs.”
  • sequence analysis software e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705. Protein analysis software matches similar sequences by assigning degrees of homology to various substitutions, deletions, and other modifications. Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine.
  • Chemical derivatives of Arresten, Canstatin and Tumstatin refers to a subject polypeptide having one or more residues chemically derivatized by reaction of a functional side group.
  • Such derivatized residues include for example, those molecules in which free amino groups have been derivatized to form amine hydrochlorides, p-toluene sulfonyl groups, carbobenzoxy groups, t-butyloxycarbonyl groups, chloroacetyl groups or formyl groups.
  • Free carboxyl groups may be derivatized to form salts, methyl and ethyl esters or other types of esters or hydrazides.
  • Free hydroxyl groups may be derivatized to form O-acyl or O-alkyl derivatives.
  • the imidazole nitrogen of histidine may be derivatized to form N- imbenzylhistidine.
  • chemical derivatives are those peptides which contain one or more naturally occurring amino acid derivatives of the twenty standard amino acids. For examples: 4-hydroxyproline may be substituted for proline; 5 -hydroxy lysine may be substitute for lysine; 3-methylhistidine may be substituted for histidine; homoserine may be substituted for serine; and ornithine may be substituted for lysine.
  • the present invention also includes fusion proteins and chimeric proteins comprising the anti-angiogenic proteins, their fragments, mutants, homologs, analogs, and allelic variants.
  • a fusion or chimeric protein can be produced as a result of recombinant expression and the cloning process, e.g., the protein may be produced comprising additional amino acids or amino acid sequences corresponding to full or partial linker sequences, e.g., the Arresten of the present invention, when produced in E. coli (see Example 2, below), comprises additional vector sequence added to the protein, including a histidine tag.
  • the term "fusion or chimeric protein" is intended to encompass changes of this type to the original protein sequence.
  • a fusion or chimeric protein can consist of a multimer of a single protein, e.g., repeats of the anti-angiogenic proteins, or the fusion and chimeric proteins can be made up of several proteins, e.g., several of the anti-angiogenic proteins.
  • the fusion or chimeric protein can comprise a combination of two or more known anti-angiogenic proteins (e.g., angiostatin and endostatin, or biologically active fragments of angiostatin and endostatin), or an anti-angiogenic protein in combination with a targeting agent (e.g., endostatin with epidermal growth factor (EGF) or RGD peptides), or an anti-angiogenic protein in combination with an immunoglobulin molecule (e.g., endostatin and IgG, specifically with the Fc portion removed).
  • a targeting agent e.g., endostatin with epidermal growth factor (EGF) or RGD peptides
  • an immunoglobulin molecule e.g., endostatin and IgG, specifically with the Fc portion removed.
  • the fusion and chimeric proteins can also include the anti-angiogenic proteins, their fragments, mutants, homologs, analogs, and allelic variants, and other anti-angiogenic proteins, e.g. , endostatin, or angiostatin.
  • Other anti-angiogenic proteins can include restin and apomigren;
  • fusion protein or "chimeric protein” as used herein can also encompass additional components for e.g., delivering a chemotherapeutic agent, wherein a polynucleotide encoding the chemotherapeutic agent is linked to the polynucleotide encoding the anti-angiogenic protein. Fusion or chimeric proteins can also encompass multimers of an anti-angiogenic protein, e.g., a dimer or trimer.
  • Such fusion or chimeric proteins can be linked together via post-translational modification (e.g., chemically linked), or the entire fusion protein may be made recombinantly.
  • Multimeric proteins comprising Arresten, Canstatin, Tumstatin, their fragments, mutants, homologs, analogs and allelic variants are also intended to be encompassed by the present invention.
  • multimer is meant a protein comprising two or more copies of a subunit protein.
  • the subunit protein may be one of the proteins of the present invention, e.g., Arresten repeated two or more times, or a fragment, mutant, homolog, analog or allelic variant, e.g., a Tumstatin mutant or fragment, e.g., Tumstatin 333, repeated two or more times.
  • a multimer may also be a fusion or chimeric protein, e.g. , a repeated tumstatin mutant may be combined with polylinker sequence, and/or one or more anti-angiogenic peptides, which may be present in a single copy, or may also be tandemly repeated, e.g. , a protein may comprise two or more multimers within the overall protein.
  • the invention also encompasses a composition comprising one or more isolated polynucleotide(s) encoding Arresten, Canstatin or Tumstatin, as well as vectors and host cells containing such a polynucleotide, and processes for producing Arresten, Canstatin and Tumstatin, and their fragments, mutants, homologs, analogs and allelic variants.
  • vector as used herein means a carrier into which pieces of nucleic acid may be inserted or cloned, which carrier functions to transfer the pieces of nucleic acid into a host cell. Such a vector may also bring about the replication and/or expression of the transferred nucleic acid pieces.
  • vectors include nucleic acid molecules derived, e.g., from a plasmid, bacteriophage, or mammalian, plant or insect virus, or non- viral vectors such as ligand-nucleic acid conjugates, liposomes, or lipid-nucleic acid complexes. It may be desirable that the transferred nucleic molecule is operatively linked to an expression control sequence to form an expression vector capable of expressing the transferred nucleic acid.
  • Such transfer of nucleic acids is generally called "transformation,” and refers to the insertion of an exogenous polynucleotide into a host cell, irrespective of the method used for the insertion. For example, direct uptake, transduction or f-mating are included.
  • the exogenous polynucleotide may be maintained as a non-integrated vector, for example, a plasmid, or alternatively, may be integrated into the host genome.
  • "Operably linked” refers to a situation wherein the components described are in a relationship permitting them to function in their intended manner, e.g., a control sequence "operably linked" to a coding sequence is ligated in such a manner that expression of the coding sequence is achieved under conditions compatible with the control sequence.
  • a "coding sequence” is a polynucleotide sequence which is transcribed into mRNA and translated into a polypeptide when placed under the control of (e.g., operably linked to) appropriate regulatory sequences.
  • the boundaries of the coding sequence are determined by a translation start codon at the 5'-terminus and a translation stop codon at the 3'-terminus. Such boundaries can be naturally-occurring, or can be introduced into or added the polynucleotide sequence by methods known in the art.
  • a coding sequence can include, but is not limited to, mRNA, cDNA, and recombinant polynucleotide sequences.
  • the vector into which the cloned polynucleotide is cloned may be chosen because it functions in a prokaryotic, or alternatively, it is chosen because it functions in a eukaryotic organism.
  • Two examples of vectors which allow for both the cloning of a polynucleotide encoding the Arresten, Canstatin and Tumstatin protein, and the expression of those proteins from the polynucleotides, are the pET22b and pET28(a) vectors (Novagen, Madison, Wisconsin, USA) and a modified pPICZ ⁇ A vector (InVitrogen, San Diego, California, USA), which allow expression of the protein in bacteria and yeast, respectively.
  • a polynucleotide Once cloned into a suitable vector, it can be transformed into an appropriate host cell.
  • host cell is meant a cell which has been or can be used as the recipient of transferred nucleic acid by means of a vector.
  • Host cells can prokaryotic or eukaryotic, mammalian, plant, or insect, and can exist as single cells, or as a collection, e.g. , as a culture, or in a tissue culture, or in a tissue or an organism.
  • Host cells can also be derived from normal or diseased tissue from a multicellular organism, e.g., a mammal.
  • Host cell as used herein, is intended to include not only the original cell which was transformed with a nucleic acid, but also descendants of such a cell, which still contain the nucleic acid.
  • the isolated polynucleotide encoding the anti-angiogenic protein additionally comprises a polynucleotide linker encoding a peptide.
  • linkers are known to those of skill in the art and, for example the linker can comprise at least one additional codon encoding at least one additional amino acid. Typically the linker comprises one to about twenty or thirty amino acids.
  • the polynucleotide linker is translated, as is the polynucleotide encoding the anti-angiogenic protein, resulting in the expression of an anti-angiogenic protein with at least one additional amino acid residue at the amino or carboxyl terminus of the anti-angiogenic protein.
  • the additional amino acid, or amino acids do not compromise the activity of the anti-angiogenic protein.
  • the vector After inserting the selected polynucleotide into the vector, the vector is transformed into an appropriate prokaryotic strain and the strain is cultured (e.g., maintained) under suitable culture conditions for the production of the biologically active anti-angiogenic protein, thereby producing a biologically active anti-angiogenic protein, or mutant, derivative, fragment or fusion protein thereof.
  • the invention comprises cloning of a polynucleotide encoding an anti-angiogenic protein into the vectors pET22b, pET17b or pET28a, which are then transformed into bacteria.
  • the bacterial host strain then expresses the anti- angiogenic protein.
  • the anti-angiogenic proteins are produced in quantities of about 10-20 milligrams, or more, per liter of culture fluid.
  • the eukaryotic vector comprises a modified yeast vector.
  • One method is to use a pPICz ⁇ plasmid wherein the plasmid contains a multiple cloning site.
  • the multiple cloning site has inserted into the multiple cloning site a His.Tag motif.
  • the vector can be modified to add a Ntiel site, or other suitable restriction sites. Such sites are well known to those of skill in the art.
  • Anti-angiogenic proteins produced by this embodiment comprise a histidine tag motif (His.tag) comprising one, or more histidines, typically about 5-20 histidines. The tag must not interfere with the anti- angiogenic properties of the protein.
  • One method of producing Arresten, Canstatin or Tumstatin is to amplify the polynucleotide of SEQ ID NO:l, SEQ LD NO:5, or SEQ LD NO:9, respectively, and clone it into an expression vector, e.g., pET22b, pET28(a), pPICZ ⁇ A, or some other expression vector, transform the vector containing the polynucleotide into a host cell capable of expressing the polypeptide encoded by the polynucleotide, culturing the transformed host cell under culture conditions suitable for expressing the protein, and then extracting and purifying the protein from the culture.
  • an expression vector e.g., pET22b, pET28(a), pPICZ ⁇ A, or some other expression vector
  • Arresten, Canstatin and Tumstatin in particular, are provided in the Examples below.
  • the Arresten, Canstatin or Tumstatin protein may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, sheep or pigs, or as a product of a transgenic plant, e.g., combined or linked with starch molecules in maize.
  • Arresten, Canstatin or Tumstatin may also be produced by conventional, known methods of chemical synthesis. Methods for constructing the proteins of the present invention by synthetic means are known to those skilled in the art.
  • the synthetically-constructed Arresten, Canstatin or Tumstatin protein sequences by virtue of sharing primary, secondary or tertiary structural and/or conformational characteristics with e.g., recombinantly-produced Arresten, Canstatin or Tumstatin, may possess biological properties in common therewith, including biological activity.
  • the synthetically-constructed Arresten, Canstatin or Tumstatin protein sequences may be employed as biologically active or immunological substitutes for e.g., recombinantly-produced, purified Arresten, Canstatin or Tumstatin protein in screening of therapeutic compounds and in immunological processes for the development of antibodies.
  • Arresten, Canstatin and Tumstatin proteins are useful in inhibiting angiogenesis, as determined in standard assays, and provided in the Examples below.
  • Arresten, Canstatin or Tumstatin do not inhibit the growth of other cells types, e.g., non-endothelial cells.
  • Polynucleotides encoding Arresten, Canstatin or Tumstatin can be cloned out of isolated DNA or a cDNA library.
  • nucleic acids polypeptides are nucleic acids or polypeptides substantially free (i.e., separated away from) the material of the biological source from which they were obtained (e.g., as exists in a mixture of nucleic acids or in cells), which may have undergone further processing.
  • isolated nucleic acids or polypeptides include nucleic acids or polypeptides obtained by methods described herein, similar methods, or other suitable methods, including essentially pure nucleic acids or polypeptides, nucleic acids or polypeptides produced by chemical synthesis, by combinations of chemical or biological methods, and recombinantly produced nucleic acids or polypeptides which are isolated.
  • An isolated polypeptide therefore means one which is relatively free of other proteins, carbohydrates, lipids, and other cellular components with which it is normally associated.
  • An isolated nucleic acid is not immediately contiguous with (i.e., covalently linked to) both of the nucleic acids with which it is immediately contiguous in the naturally-occurring genome of the organism from which the nucleic acid is derived.
  • the term therefore, includes, for example, a nucleic acid which is incorporated into a vector (e.g., an autonomously replicating virus or plasmid), or a nucleic acid which exists as a separate molecule independent of other nucleic acids such as a nucleic acid fragment produced by chemical means or restriction endonuclease treatment.
  • the polynucleotides and proteins of the present invention can also be used to design probes to isolate other anti-angiogenic proteins. Exceptional methods are provided in U.S. Pat. No. 5,837,490, by Jacobs et al, the entire teachings of which are herein incorporated by reference in their entirety.
  • the design of the oligonucleotide probe should preferably follow these parameters: (a) It should be designed to an area of the sequence which has the fewest ambiguous bases ("N's"), if any, and (b) It should be designed to have a T m of approx. 80 °C (assuming 2°C for each A or T and 4 degrees for each G or C).
  • the oligonucleotide should preferably be labeled with g- 32 P-ATP (specific activity 6000 Ci/mmole) and T4 polynucleotide kinase using commonly employed techniques for labeling oligonucleotides. Other labeling techniques can also be used. Unincorporated label should preferably be removed by gel filtration chromatography or other established methods. The amount of radioactivity incorporated into the probe should be quantitated by measurement in a scintillation counter. Preferably, specific activity of the resulting probe should be approximately 4 x 10 6 dpm/pmole.
  • the bacterial culture containing the pool of full-length clones should preferably be thawed and 100 ⁇ l of the stock used to inoculate a sterile culture flask containing 25 ml of sterile L-broth containing ampicillin at 100 ⁇ g/ml.
  • the culture should preferably be grown to saturation at 37 °C, and the saturated culture should preferably be diluted in fresh L-broth.
  • Aliquots of these dilutions should preferably be plated to determine the dilution and volume which will yield approximately 5000 distinct and well-separated colonies on solid bacteriological media containing L-broth containing ampicillin at 100 ⁇ g/ml and agar at 1.5% in a 150 mm petri dish when grown overnight at 37 °C. Other known methods of obtaining distinct, well-separated colonies can also be employed.
  • Highly stringent condition are those that are at least as stringent as, for example, lx SSC at 65 °C, or lx SSC and 50% formamide at 42°C.
  • Moderate stringency conditions are those that are at least as stringent as 4x SSC at 65 °C, or 4x SSC and 50% formamide at 42°C.
  • Reduced stringency conditions are those that are at least as stringent as 4x SSC at 50°C, or 6x SSC and 50% formamide at 40°C.
  • the filter is then preferably incubated at 65 °C for 1 hour with gentle agitation in ⁇ .times.
  • SSC 20x stock is 175.3 g NaCl/liter, 88.2 g Na citrate/liter, adjusted to pH 7.0 with NaOH) containing 0.5% SDS, 100 ⁇ g/ml of yeast RNA, and 10 mM EDTA (approximately 10 mL per 150 mm filter).
  • the probe is then added to the hybridization mix at a concentration greater than or equal to 1 x 10 6 dpm mL.
  • the filter is then preferably incubated at 65 °C with gentle agitation overnight.
  • the filter is then preferably washed in 500 mL of 2x SSC/0.5% SDS at room temperature without agitation, preferably followed by 500 mL of 2x SSC/0.1% SDS at room temperature with gentle shaking for 15 minutes. A third wash with O.lx SSC/0.5% SDS at 65 °C for 30 minutes to 1 hour is optional.
  • the filter is then preferably dried and subjected to autoradiography for sufficient time to visualize the positives on the X-ray film. Other known hybridization methods can also be employed.
  • the positive colonies are then picked, grown in culture, and plasmid DNA isolated using standard procedures. The clones can then be verified by restriction analysis, hybridization analysis, or DNA sequencing.
  • the present invention includes methods of inhibiting angiogenesis in mammalian tissue using Arresten, Canstatin, Tumstatin or their biologically-active fragments, analogs, homologs, derivatives or mutants.
  • the present invention includes methods of treating an angiogenesis-mediated disease with an effective amount of one or more of the anti-angiogenic proteins, or one or more biologically active fragment thereof, or combinations of fragments that possess anti- angiogenic activity, or agonists and antagonists.
  • An effective amount of anti- angiogenic protein is an amount sufficient to inhibit the angiogenesis which results in the disease or condition, thus completely, or partially, alleviating the disease or condition.
  • Alleviation of the angiogenesis-mediated disease can be determined by observing an alleviation of symptoms of the disease, e.g., a reduction in the size of a tumor, or arrested tumor growth.
  • the term "effective amount” also means the total amount of each active component of the composition or method that is sufficient to show a meaningful patient benefit, i.e., treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions.
  • the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.
  • Angiogenesis-mediated diseases include, but are not limited to, cancers, solid tumors, blood-born tumors (e.g.
  • leukemias tumor metastasis
  • benign tumors e.g., hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas
  • rheumatoid arthritis e.g., rheumatoid arthritis
  • psoriasis e.g., ocular angiogenic diseases (e.g., diabetic retmopathy, retmopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis), Osier- Webber Syndrome, myocardial angiogenesis, plaque neovascularization, telangiectasia, hemophiliac joints, angiofibroma, and wound granulation.
  • benign tumors e.g., hemangiomas, acoustic neuromas, neurofibromas, trachomas, and py
  • the anti- angiogenic proteins are useful in the treatment of diseases of excessive or abnormal stimulation of endothelial cells. These diseases include, but are not limited to, intestinal adhesions, Crohn's disease, atherosclerosis, scleroderma, and hypertrophic scars (i.e., keloids).
  • the anti-angiogenic proteins can be used as a birth control agent by preventing vascularization required for embryo implantation.
  • the anti- angiogenic proteins are useful in the treatment of diseases that have angiogenesis as a pathologic consequence such as cat scratch disease (Rochele minalia quintosa) and ulcers (Heliobacter pylori).
  • the anti-angiogenic proteins can also be used to prevent dialysis graft vascular access stenosis, and obesity, e.g., by inhibiting capillary formation in adipose tissue, thereby preventing its expansion.
  • the anti-angiogenic proteins can also be used to treat localized (e.g., nonmetastisized) diseases.
  • "Cancer” means neoplastic growth, hyperplastic or proliferative growth or a pathological state of abnormal cellular development and includes solid tumors, non- solid tumors, and any abnormal cellular proliferation, such as that seen in leukemia.
  • cancer also means angiogenesis-dependent cancers and tumors, i.e., tumors that require for their growth (expansion in volume and/or mass) an increase in the number and density of the blood vessels supplying them with blood.
  • regression refers to the reduction of tumor mass and size as determined using methods well-known to those of skill in the art.
  • antibodies or antisera to the anti-angiogenic proteins can be used to block localized, native anti-angiogenic proteins and processes, and thereby increase formation of new blood vessels so as to inhibit atrophy of tissue.
  • the anti-angiogenic proteins may be used in combination with other compositions and procedures for the treatment of diseases.
  • a tumor may be treated conventionally with surgery, radiation, chemotherapy, or immunotherapy, combined with the anti-angiogenic proteins and then the anti- angiogenic proteins may be subsequently administered to the patient to extend the dormancy of micrometastases and to stabilize and inhibit the growth of any residual primary tumor.
  • the anti-angiogenic proteins, or fragments, antisera, receptor agonists, or receptor antagonists thereof, or combinations thereof can also be combined with other anti-angiogenic compounds, or proteins, fragments, antisera, receptor agonists, receptor antagonists of other anti-angiogenic proteins (e.g., angiostatin, endostatin).
  • compositions of the present invention are combined with pharmaceutically acceptable excipients, and optionally sustained- release matrix, such as biodegradable polymers, to form therapeutic compositions.
  • the compositions of the present invention may also contain other anti-angiogenic proteins or chemical compounds, such as endostatin or angiostatin, and mutants, fragments, and analogs thereof.
  • the compositions may further contain other agents which either enhance the activity of the protein or compliment its activity or use in treatment, such as chemotherapeutic or radioactive agents. Such additional factors and/or agents may be included in the composition to produce a synergistic effect with protein of the invention, or to minimize side effects.
  • administration of the composition of the present invention may be administered concurrently with other therapies, e.g., administered in conjunction with a chemotherapy or radiation therapy regimen.
  • the invention includes methods for inhibiting angiogenesis in mammalian tissues by contacting the tissue with a composition comprising the proteins of the invention.
  • contacting is meant not only topical application, but also those modes of delivery that introduce the composition into the tissues, or into the cells of the tissues.
  • a sustained-release matrix is a matrix made of materials, usually polymers, which are degradable by enzymatic or acid/base hydrolysis or by dissolution. Once inserted into the body, the matrix is acted upon by enzymes and body fluids.
  • the sustained-release matrix desirably is chosen from biocompatible materials such as liposomes, polylactides (polylactic acid), polyglycolide (polymer of glycolic acid), polylactide co-glycolide (co-polymers of lactic acid and glycolic acid) polyanhydrides, poly(ortho)esters, polyproteins, hyaluronic acid, collagen, chondroitin sulfate, carboxylic acids, fatty acids, phospholipids, polysaccharides, nucleic acids, polyamino acids, amino acids such as phenylalanine, tyrosine, isoleucine, polynucleotides, polyvinyl propylene, polyvinylpyrrolidone and silicone.
  • a preferred biodegradable matrix is a matrix of one of either polylactide, polyglycolide, or polylactide co-glycolide (co-polymers of lactic acid and glycolic acid).
  • the angiogenesis-modulating composition of the present invention may be a solid, liquid or aerosol and may be administered by any known route of administration.
  • solid compositions include pills, creams, and implantable dosage units.
  • the pills may be administered orally, the therapeutic creams may be administered topically.
  • the implantable dosage unit may be administered locally, for example at a tumor site, or which may be implanted for systemic release of the angiogenesis-modulating composition, for example subcutaneously.
  • liquid composition include formulations adapted for injection subcutaneously, intravenously, intraarterially, and formulations for topical and intraocular administration.
  • aerosol formulation include inhaler formulation for administration to the lungs.
  • the proteins and protein fragments with the anti-angiogenic activity described above can be provided as isolated and substantially purified proteins and protein fragments in pharmaceutically acceptable formulations using formulation methods known to those of ordinary skill in the art. These formulations can be administered by standard routes. In general, the combinations may be administered by the topical, transdermal, intraperitoneal, intracranial, intracerebroventricular, intracerebral, intravaginal, intrauterine, oral, rectal or parenteral (e.g., intravenous, intraspinal, subcutaneous or intramuscular) route.
  • parenteral e.g., intravenous, intraspinal, subcutaneous or intramuscular
  • the anti-angiogenic proteins may be incorporated into biodegradable polymers allowing for sustained release of the compound, the polymers being implanted in the vicinity of where drug delivery is desired, for example, at the site of a tumor or implanted so that the anti- angiogenic proteins are slowly released systemically.
  • Osmotic minipumps may also be used to provide controlled delivery of high concentrations of the anti-angiogenic proteins through cannulae to the site of interest, such as directly into a metastatic growth or into the vascular supply to that tumor.
  • the biodegradable polymers and their use are described, for example, in detail in Brem et al. (1991) (J. Neurosurg. 74:441-446), which is hereby incorporated by reference in its entirety.
  • compositions containing a polypeptide of this invention can be administered intravenously, as by injection of a unit dose, for example.
  • unit dose when used in reference to a therapeutic composition of the present invention refers to physically discrete units suitable as unitary dosage for the subject, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required diluent; i.e., carrier or vehicle.
  • compositions of the present inventions include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.
  • Pharmaceutical compositions for parenteral injection comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use.
  • aqueous and nonaqueous carriers, diluents, solvents or vehicles examples include water, ethanol, polyois (e.g., glycerol, propylene glycol, polyethylene glycol and the like), carboxymethylcellulose and suitable mixtures thereof, vegetable oils (e.g., olive oil) and injectable organic esters such as ethyl oleate.
  • polyois e.g., glycerol, propylene glycol, polyethylene glycol and the like
  • carboxymethylcellulose and suitable mixtures thereof examples include water, ethanol, polyois (e.g., glycerol, propylene glycol, polyethylene glycol and the like), carboxymethylcellulose and suitable mixtures thereof, vegetable oils (e.g., olive oil) and injectable organic esters such as ethyl oleate.
  • vegetable oils e.g., olive oil
  • injectable organic esters such as ethyl oleate.
  • Proper fluidity may be maintained,
  • Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycohde, poly(orthoesters) and poly(anhydrides).
  • Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.
  • the injectable formulations may be sterilized, for example, by filtration through a bacterial-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable media just prior to use.
  • the therapeutic compositions of the present invention can include pharmaceutically acceptable salts of the components therein, e.g., which may be derived from inorganic or organic acids.
  • salts are, within the scope of sound medical judgement, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like and are commensurate with a reasonable benefit/risk ratio.
  • Pharmaceutically acceptable salts are well-known in the art. For example, S. M. Berge, et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences ( 1977) 66 : 1 et seq. , which is incorporated herein by reference.
  • Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the polypeptide) that are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, tartaric, mandelic and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine and the like. The salts may be prepared in situ during the final isolation and purification of the compounds of the invention or separately by reacting a free base function with a suitable organic acid.
  • inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, tartaric, mandelic and the like.
  • Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example
  • Representative acid addition salts include, but are not limited to acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsufonate, digluconate, glycerophosphate, hemisulfate, heptonoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxymethanesulfonate (isethionate), lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartate, thiocyanate, phosphate, glutamate, bicarbonate, p-toluenesulfonate and undecanoate.
  • the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; arylalkyl halides like benzyl and phenethyl bromides and others. Water or oil-soluble or dispersible products are thereby obtained.
  • lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides
  • dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates
  • long chain halides such as dec
  • compositions, carriers, diluents and reagents are used interchangeably and represent that the materials are capable of administration to or upon a mammal with a minimum of undesirable physiological effects such as nausea, dizziness, gastric upset and the like.
  • physiologically tolerable and grammatical variations thereof as they refer to compositions, carriers, diluents and reagents, are used interchangeably and represent that the materials are capable of administration to or upon a mammal with a minimum of undesirable physiological effects such as nausea, dizziness, gastric upset and the like.
  • the preparation of a pharmacological composition that contains active ingredients dissolved or dispersed therein is well understood in the art and need not be limited based on formulation.
  • Such compositions are prepared as injectables either as liquid solutions or suspensions, however, solid forms suitable for solution, or suspensions, in liquid prior to use can also be prepared.
  • the preparation can also be emulsified.
  • the active ingredient can be mixed with excipeints which are pharmaceutically acceptable and compatible with the active ingredient and in amounts suitable for use in the therapeutic methods described herein.
  • Suitable excipients include, for example, water, saline, dextrose, glycerol, ethanol or the like and combinations thereof.
  • the composition can contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like which enhance the effectiveness of the active ingredient.
  • the anti-angiogenic proteins of the present invention can also be included in a composition comprising a prodrug.
  • prodrug refers to compounds which are rapidly transformed in vivo to yield the parent compound, for example, by enzymatic hydrolysis in blood.
  • T. Higuchi and N. Stella Prodrugs as Novel Delivery Systems, Vol. 14 of the ACS Symposium Series and in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Permagon Press, 1987, both of which are incorporated herein by reference.
  • the term "pharmaceutically acceptable prodrug” refers to (1) those prodrugs of the compounds of the present invention which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of humans and animals without undue toxicity, irritation, allergic response and the like, commensurate with a suitable benefit-to-risk ratio and effective for their intended use and (2) zwitterionic forms, where possible, of the parent compound.
  • the dosage of the anti-angiogenic proteins of the present invention will depend on the disease state or condition being treated and other clinical factors such as weight and condition of the human or animal and the route of administration of the compound. For treating humans or animals, about 10 mg/kg of body weight to about 20 mg/kg of body weight of the protein can be administered. In combination therapies, e.g., the proteins of the invention in combination with radiotherapy, chemotherapy, or immunotherapy, it may be possible to reduce the dosage, e.g., to about 0.1 mg/kg of body weight to about 0.2 mg/kg of body weight. Depending upon the half-life of the anti-angiogenic proteins in the particular animal or human, the anti-angiogenic proteins can be administered between several times per day to once a week.
  • the present invention has application for both human and veterinary use.
  • the methods of the present invention contemplate single as well as multiple administrations, given either simultaneously or over an extended period of time.
  • the anti-angiogenic proteins can be administered in conjunction with other forms of therapy, e.g., chemotherapy, radiotherapy, or immunotherapy.
  • the anti-angiogenic protein formulations include those suitable for oral, rectal, ophthalmic (including intravitreal or intracameral), nasal, topical (including buccal and sublingual), intrauterine, vaginal or parenteral (including subcutaneous, intraperitoneal, intramuscular, intravenous, intradermal, intracranial, intratracheal, and epidural) administration.
  • the anti-angiogenic protein formulations may conveniently be presented in unit dosage form and may be prepared by conventional pharmaceutical techniques. Such techniques include the step of bringing into association the active ingredient and the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
  • Formulations suitable for parenteral administration include aqueous and nonaqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
  • the formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, water for injections, immediately prior to use.
  • Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
  • the anti-angiogenic proteins of the present invention will be in the form of a tablet, capsule, powder, solution or elixir.
  • the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant.
  • the tablet, capsule, and powder contain from about 5 to 95% protein of the present invention, and preferably from about 25 to 90% protein of the present invention.
  • a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils may be added.
  • the liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol.
  • the pharmaceutical composition When administered in liquid form, contains from about 0.5 to 90% by weight of protein of the present invention, and preferably from about 1 to 50% protein of the present invention.
  • protein of the present invention When an effective amount of protein of the present invention is administered by intravenous, cutaneous or subcutaneous injection, protein of the present invention will be in the form of a pyrogen-free, parenterally acceptable aqueous solution.
  • a preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to protein of the present invention, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art.
  • the pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art.
  • the amount of protein of the present invention in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone. Ultimately, the attending physician will decide the amount of protein of the present invention with which to treat each individual patient. Initially, the attending physician will admimster low doses of protein of the present invention and observe the patient's response. Larger doses of protein of the present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further.
  • the duration of intravenous therapy using the pharmaceutical composition of the present invention will vary, depending on the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient. It is contemplated that the duration of each application of the protein of the present invention will be in the range of 12 to 24 hours of continuous intravenous admimstration. Ultimately the attending physician will decide on the appropriate duration of intravenous therapy using the pharmaceutical composition of the present invention.
  • Preferred unit dosage formulations are those containing a daily dose or unit, daily sub-dose, or an appropriate fraction thereof, of the administered ingredient. It should be understood that in addition to the ingredients, particularly mentioned above, the formulations of the present invention may include other agents conventional in the art having regard to the type of formulation in question. Optionally, cytotoxic agents may be incorporated or otherwise combined with the anti-angiogenic proteins, or biologically functional protein fragements thereof, to provide dual therapy to the patient.
  • the therapeutic compositions are also presently valuable for veterinary applications.
  • Particularly domestic animals and thoroughbred horses, in addition to humans, are desired patients for such treatment with proteins of the present invention.
  • Cytotoxic agents such as ricin
  • Proteins linked to cytotoxic agents are infused in a manner designed to maximize delivery to the desired location. For example, ricin-linked high affinity fragments are delivered through a cannula into vessels supplying the target site or directly into the target.
  • Such agents are also delivered in a controlled manner through osmotic pumps coupled to infusion cannulae.
  • a combination of antagonists to the anti-angiogenic proteins may be co- applied with stimulators of angiogenesis to increase vascularization of tissue. This therapeutic regimen provides an effective means of destroying metastatic cancer.
  • Additional treatment methods include administration of the anti-angiogenic proteins, fragments, analogs, antisera, or receptor agonists and antagonists thereof, linked to cytotoxic agents.
  • the anti-angiogenic proteins can be human or animal in origin.
  • the anti-angiogenic proteins can also be produced synthetically by chemical reaction or by recombinant techniques in conjunction with expression systems.
  • the anti-angiogenic proteins can also be produced by enzymatically cleaving isolated Type IV collagen to generate proteins having anti-angiogenic activity.
  • the anti-angiogenic proteins may also be produced by compounds that mimic the action of endogenous enzymes that cleave Type JN collagen to the anti-angiogenic proteins. Production of the anti-angiogenic proteins may also be modulated by compounds that affect the activity of cleavage enzymes.
  • the present invention also encompasses gene therapy whereby a polynucleotide encoding the anti-angiogenic proteins, or a mutant, fragment, or fusion protein thereof, is introduced and regulated in a patient.
  • gene therapy encompasses incorporation of D ⁇ A sequences into somatic cells or germ line cells for use in either ex vivo or in vivo therapy.
  • Gene therapy functions to replace genes, augment normal or abnormal gene function, and to combat infectious diseases and other pathologies.
  • Strategies for treating these medical problems with gene therapy include therapeutic strategies such as identifying the defective gene and then adding a functional gene to either replace the function of the defective gene or to augment a slightly functional gene; or prophylactic strategies, such as adding a gene for the product protein that will treat the condition or that will make the tissue or organ more susceptible to a treatment regimen.
  • a gene such as that encoding one or more of the anti-angiogenic proteins may be placed in a patient and thus prevent occurrence of angiogenesis; or a gene that makes tumor cells more susceptible to radiation could be inserted and then radiation of the tumor would cause increased killing of the tumor cells.
  • Gene transfer methods for gene therapy fall into three broad categories: physical (e.g., electroporation, direct gene transfer and particle bombardment), chemical (e.g., lipid-based carriers, or other non- viral vectors) and biological (e.g., virus-derived vector and receptor uptake).
  • non- viral vectors may be used which include liposomes coated with DNA.
  • liposome/DNA complexes may be directly injected intravenously into the patient. It is believed that the liposome/DNA complexes are concentrated in the liver where they deliver the DNA to macrophages and Kupffer cells. These cells are long lived and thus provide long term expression of the delivered DNA.
  • vectors or the "naked" DNA of the gene may be directly injected into the desired organ, tissue or tumor for targeted delivery of the therapeutic DNA.
  • Gene therapy methodologies can also be described by delivery site.
  • ex vivo gene transfer cells are taken from the patient and grown in cell culture. The DNA is transfected into the cells, the transfected cells are expanded in number and then reimplanted in the patient.
  • in vitro gene transfer the transformed cells are cells growing in culture, such as tissue culture cells, and not particular cells from a particular patient. These "laboratory cells" are transfected, the transfected cells are selected and expanded for either implantation into a patient or for other uses.
  • In vivo gene transfer involves introducing the DNA into the cells of the patient when the cells are within the patient. Methods include using virally mediated gene transfer using a noninfectious virus to deliver the gene in the patient or injecting naked DNA into a site in the patient and the DNA is taken up by a percentage of cells in which the gene product protein is expressed. Additionally, the other methods described herein, such as use of a "gene gun,” may be used for in vitro insertion of the DNA or regulatory sequences controlling production of the anti-angiogenic proteins.
  • Chemical methods of gene therapy may involve a lipid based compound, not necessarily a liposome, to transfer the DNA across the cell membrane.
  • Lipofectins or cytofectins lipid-based positive ions that bind to negatively charged DNA, make a complex that can cross the cell membrane and provide the DNA into the interior of the cell.
  • Another chemical method uses receptor-based endocytosis, which involves binding a specific ligand to a cell surface receptor and enveloping and transporting it across the cell membrane. The ligand binds to the DNA and the whole complex is transported into the cell.
  • the ligand gene complex is injected into the blood stream and then target cells that have the receptor will specifically bind the ligand and transport the ligand-DNA complex into the cell.
  • viral vectors to insert genes into cells.
  • altered retrovirus vectors have been used in ex vivo methods to introduce genes into peripheral and tumor-infiltrating lymphocytes, hepatocytes, epidermal cells, myocytes, or other somatic cells. These altered cells are then introduced into the patient to provide the gene product from the inserted DNA.
  • Viral vectors have also been used to insert genes into cells using in vivo protocols. To direct the tissue-specific expression of foreign genes, cis-acting regulatory elements or promoters that are known to be tissue-specific can be used. Alternatively, this can be achieved using in situ delivery of DNA or viral vectors to specific anatomical sites in vivo.
  • gene transfer to blood vessels in vivo was achieved by implanting in vitro transduced endothelial cells in chosen sites on arterial walls.
  • the virus infected surrounding cells which also expressed the gene product.
  • a viral vector can be delivered directly to the in vivo site, by a catheter for example, thus allowing only certain areas to be infected by the virus, and providing long-term, site specific gene expression.
  • retrovirus vectors has also been demonstrated in mammary tissue and hepatic tissue by injection of the altered virus into blood vessels leading to the organs.
  • Viral vectors that have been used for gene therapy protocols include but are not limited to, retroviruses, other RNA viruses such as poliovirus or Sindbis virus, adenovirus, adeno-associated virus, herpes viruses, SV 40, vaccinia and other DNA viruses.
  • Replication-defective murine retroviral vectors are the most widely utilized gene transfer vectors.
  • Murine leukemia retroviruses are composed of a single strand RNA complexed with a nuclear core protein and polymerase (pol) enzymes, encased by a protein core (gag) and surrounded by a glycoprotein envelope (env) that determines host range.
  • retroviral vector systems exploit the fact that a minimal vector containing the 5' and 3' LTRs and the packaging signal are sufficient to allow vector packaging, infection and integration into target cells providing that the viral structural proteins are supplied in trans in the packaging cell line. Fundamental advantages of retroviral vectors for gene transfer include efficient infection and gene expression in most cell types, precise single copy vector integration into target cell chromosomal DNA, and ease of manipulation of the retroviral genome.
  • the adenovirus is composed of linear, double stranded DNA complexed with core proteins and surrounded with capsid proteins. Advances in molecular virology have led to the ability to exploit the biology of these organisms to create vectors capable of transducing novel genetic sequences into target cells in vivo.
  • Adenoviral- based vectors will express gene product proteins at high levels.
  • Adenoviral vectors have high efficiencies of infectivity, even with low titers of virus. Additionally, the virus is fully infective as a cell free virion so injection of producer cell lines are not necessary. Another potential advantage to adenoviral vectors is the ability to achieve long term expression of heterologous genes in vivo.
  • DNA delivery include fusogenic lipid vesicles such as liposomes or other vesicles for membrane fusion, lipid particles of DNA incorporating cationic lipid such as lipofectin, polylysine-mediated transfer of DNA, direct injection of DNA, such as micro injection of DNA into germ or somatic cells, pneumatically delivered DNA-coated particles, such as the gold particles used in a "gene gun,” and inorganic chemical approaches such as calcium phosphate transfection. Particle-mediated gene transfer methods were first used in transforming plant tissue. With a particle bombardment device, or “gene gun,” a motive force is generated to accelerate DNA-coated high density particles (such as gold or tungsten) to a high velocity that allows penetration of the target organs, tissues or cells.
  • a motive force is generated to accelerate DNA-coated high density particles (such as gold or tungsten) to a high velocity that allows penetration of the target organs, tissues or cells.
  • Particle bombardment can be used in in vitro systems, or with ex vivo or in vivo techniques to introduce DNA into cells, tissues or organs.
  • Another method, ligand-mediated gene therapy involves complexing the DNA with specific ligands to form ligand-DNA conjugates, to direct the DNA to a specific cell or tissue. It has been found that injecting plasmid DNA into muscle cells yields high percentage of the cells which are transfected and have sustained expression of marker genes.
  • the DNA of the plasmid may or may not integrate into the genome of the cells.
  • Non-integration of the transfected DNA would allow the transfection and expression of gene product proteins in terminally differentiated, non-proliferative tissues for a prolonged period of time without fear of mutational insertions, deletions, or alterations in the cellular or mitochondrial genome.
  • Long-term, but not necessarily permanent, transfer of therapeutic genes into specific cells may provide treatments for genetic diseases or for prophylactic use.
  • the DNA could be reinjected periodically to maintain the gene product level without mutations occurring in the genomes of the recipient cells.
  • Non-integration of exogenous DNAs may allow for the presence of several different exogenous DNA constructs within one cell with all of the constructs expressing various gene products.
  • Electroporation for gene transfer uses an electrical current to make cells or tissues susceptible to electroporation-mediated mediated gene transfer.
  • a brief electric impulse with a given field strength is used to increase the permeability of a membrane in such a way that DNA molecules can penetrate into the cells.
  • This technique can be used in in vitro systems, or with ex vivo or in vivo techniques to introduce DNA into cells, tissues or organs.
  • Carrier mediated gene transfer in vivo can be used to transfect foreign DNA into cells.
  • the carrier-DNA complex can be conveniently introduced into body fluids or the bloodstream and then site-specifically directed to the target organ or tissue in the body. Both liposomes and polycations, such as polylysine, lipofectins or cytofectins, can be used.
  • Liposomes can be developed which are cell specific or organ specific and thus the foreign DNA carried by the liposome will be taken up by target cells. Injection of immunoliposomes that are targeted to a specific receptor on certain cells can be used as a convenient method of inserting the DNA into the cells bearing the receptor.
  • Another carrier system that has been used is the asialoglycoportein/polylysine conjugate system for carrying DNA to hepatocytes for in vivo gene transfer.
  • the transfected DNA may also be complexed with other kinds of carriers so that the DNA is carried to the recipient cell and then resides in the cytoplasm or in the nucleoplasm.
  • DNA can be coupled to carrier nuclear proteins in specifically engineered vesicle complexes and carried directly into the nucleus.
  • Gene regulation of the anti-angiogenic proteins may be accomplished by administering compounds that bind to the gene encoding one of the anti-angiogenic proteins, or control regions associated with the gene, or its corresponding RNA transcript to modify the rate of transcription or translation.
  • cells transfected with a DNA sequence encoding the anti-angiogenic proteins may be administered to a patient to provide an in vivo source of those proteins.
  • cells may be transfected with a vector containing a nucleic acid sequence encoding the anti-angiogenic proteins.
  • the transfected cells may be cells derived from the patient's normal tissue, the patient's diseased tissue, or may be non-patient cells.
  • tumor cells removed from a patient can be transfected with a vector capable of expressing the proteins of the present invention, and re-introduced into the patient.
  • the transfected tumor cells produce levels of the protein in the patient that inhibit the growth of the tumor.
  • Patients may be human or non-human animals.
  • Cells may also be transfected by non- vector, or physical or chemical methods known in the art such as electroporation, ionoporation, or via a "gene gun.”
  • the DNA may be directly injected, without the aid of a carrier, into a patient.
  • the DNA may be injected into skin, muscle or blood.
  • the gene therapy protocol for transfecting the anti-angiogenic proteins into a patient may either be through integration of the anti-angiogenic protein DNA into the genome of the cells, into minichromosomes or as a separate replicating or non- replicating DNA construct in the cytoplasm or nucleoplasm of the cell. Expression of the anti-angiogenic proteins may continue for a long-period of time or may be reinjected periodically to maintain a desired level of the protein(s) in the cell, the tissue or organ or a determined blood level.
  • the invention encompasses antibodies and antisera, which can be used for testing of novel anti-angiogenic proteins, and can also be used in diagnosis, prognosis, or treatment of diseases and conditions characterized by, or associated with, angiogenic activity or lack thereof.
  • antibodies and antisera can also be used to up-regulate angiogenesis where desired, e.g., in post-infarct heart tissue, antibodies or antisera to the proteins of the invention can be used to block localized, native anti-angiogenic proteins and processes, and increase formation of new blood vessels and inhibit atrophy of heart tissue.
  • antibody or “antibody molecule” refers to a population of immunoglobulin molecules and/or immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antibody combining site or paratope.
  • Passive antibody therapy using antibodies that specifically bind the anti- angiogenic proteins can be employed to modulate angiogenic-dependent processes such as reproduction, development, and wound healing and tissue repair.
  • antisera directed to the Fab regions of antibodies of the anti-angiogenic proteins can be administered to block the ability of endogenous antisera to the proteins to bind the proteins.
  • the anti-angiogenic proteins of the present invention also can be used to generate antibodies that are specific for the inhibitor(s) and receptor(s).
  • the antibodies can be either polyclonal antibodies or monoclonal antibodies. These antibodies that specifically bind to the anti-angiogenic proteins or their ⁇ receptors can be used in diagnostic methods and kits that are well known to those of ordinary skill in the art to detect or quantify the anti-angiogenic proteins or their receptors in a body fluid or tissue. Results from these tests can be used to diagnose or predict the occurrence or recurrence of a cancer and other angiogenic mediated diseases.
  • the invention also includes use of the anti-angiogenic proteins, antibodies to those proteins, and compositions comprising those proteins and/or their antibodies in diagnosis or prognosis of diseases characterized by angiogenic activity.
  • prognostic method means a method that enables a prediction regarding the progression of a disease of a human or animal diagnosed with the disease, in particular, an angiogenesis dependent disease.
  • diagnostic method as used herein means a method that enables a determination of the presence or type of angiogenesis-dependent disease in or on a human or animal.
  • the the anti-angiogenic proteins can be used in a diagnostic method and kit to detect and quantify antibodies capable of binding the proteins. These kits would permit detection of circulating antibodies to the anti-angiogenic proteins which indicates the spread of micrometastases in the presence of the anti-angiogenic proteins secreted by primary tumors in situ. Patients that have such circulating anti- protein antibodies may be more likely to develop multiple tumors and cancers, and may be more likely to have recurrences of cancer after treatments or periods of remission.
  • the Fab fragments of these anti-protein antibodies may be used as antigens to generate anti-protein Fab-fragment antisera which can be used to neutralize anti-protein antibodies. Such a method would reduce the removal of circulating protein by anti-protein antibodies, thereby effectively elevating circulating levels of the anti-angiogenic proteins.
  • the present invention also includes isolation of receptors specific for the anti-angiogenic proteins. Protein fragments that possess high affinity binding to tissues can be used to isolate the receptor of the anti-angiogenic proteins on affinity columns. Isolation and purification of the receptor(s) is a fundamental step towards elucidating the mechanism of action of the anti-angiogenic proteins. Isolation of a receptor and identification of agonists and antagonists will facilitate development of drugs to modulate the activity of the receptor, the final pathway to biological activity. Isolation of the receptor enables the construction of nucleotide probes to monitor the location and synthesis of the receptor, using in situ and solution hybridization technology. Further, the gene for the receptor can be isolated, incorporated into an expression vector and transfected into cells, such as patient tumor cells to increase the ability of a cell type, tissue or tumor to bind the anti- angiogenic proteins and inhibit local angiogenesis.
  • the anti-angiogenic proteins are employed to develop affinity columns for isolation of the receptor(s) for the anti-angiogenic proteins from cultured tumor cells. Isolation and purification of the receptor is followed by amino acid sequencing. Using this information the gene or genes coding for the receptor can be identified and isolated. Next, cloned nucleic acid sequences are developed for insertion into vectors capable of expressing the receptor. These techniques are well known to those skilled in the art. Transfection of the nucleic acid sequence(s) coding for the receptor into tumor cells, and expression of the receptor by the transfected tumor cells enhances the responsiveness of these cells to endogenous or exogenous anti-angiogenic proteins and thereby decreasing the rate of metastatic growth.
  • Angiogenesis-inhibiting proteins of the present invention can be synthesized in a standard microchemical facility and purity checked with HPLC and mass spectrophotometry. Methods of protein synthesis, HPLC purification and mass spectrophotometry are commonly known to those skilled in these arts.
  • the anti- angiogenic proteins and their receptors proteins are also produced in recombinant E. coli or yeast expression systems, and purified with column chromatography.
  • Different protein fragments of the intact the anti-angiogenic proteins can be synthesized for use in several applications including, but not limited to the following; as antigens for the development of specific antisera, as agonists and antagonists active at binding sites of the anti-angiogenic proteins, as proteins to be linked to, or used in combination with, cytotoxic agents for targeted killing of cells that bind the anti-angiogenic proteins.
  • the synthetic protein fragments of the anti-angiogenic proteins have a variety of uses.
  • the protein that binds to the receptor(s) of the anti-angiogenic proteins with high specificity and avidity is radiolabeled and employed for visualization and quantitation of binding sites using autoradiographic and membrane binding techniques. This application provides important diagnostic and research tools. Knowledge of the binding properties of the receptor(s) facilitates investigation of the transduction mechanisms linked to the receptor(s).
  • the anti-angiogenic proteins and proteins derived from them can be coupled to other molecules using standard methods.
  • the amino and carboxyl termini of the anti-angiogenic proteins both contain tyrosine and lysine residues and are isotopically and nonisotopically labeled with many techniques, for example radiolabeling using conventional techniques (tyrosine residues-chloramine T, iodogen, lactoperoxidase; lysine residues-Bolton-Hunter reagent). These coupling techniques are well known to those skilled in the art. Alternatively, tyrosine or lysine is added to fragments that do not have these residues to facilitate labeling of reactive amino and hydroxyl groups on the protein.
  • the coupling technique is chosen on the basis of the functional groups available on the amino acids including, but not limited to amino, sulfhydral, carboxyl, amide, phenol, and imidazole.
  • Various reagents used to effect these couplings include among others, glutaraldehyde, diazotized benzidine, carbodiimide, and p-benzoquinone.
  • the anti-angiogenic proteins are chemically coupled to isotopes, enzymes, carrier proteins, cytotoxic agents, fluorescent molecules, chemiluminescent, bioluminescent and other compounds for a variety of applications.
  • the efficiency of the coupling reaction is determined using different techniques appropriate for the specific reaction. For example, radiolabeling of a protein of the present invention with I is accomplished using chloramine T and Na I of high specific activity. The reaction is terminated with sodium metabisulfite and the mixture is desalted on disposable columns. The labeled protein is eluted from the column and fractions are collected. Aliquots are removed from each fraction and radioactivity measured in a gamma counter. In this manner, the unreacted Na 125 I is separated from the labeled protein. The protein fractions with the highest specific radioactivity are stored for subsequent use such as analysis of the ability to bind to antisera of the anti- angiogenic proteins.
  • labeling the anti-angiogenic proteins with short lived isotopes enables visualization of receptor binding sites in vivo using positron emission tomography or other modern radiographic techniques to locate tumors with the proteins' binding sites.
  • Example 1 Isolation of Native Arresten.
  • Arresten can be generated in milligram quantities from human placenta and amnion tissue.
  • the protocol for isolating this and similar proteins has been described by others (e.g., Langeveld, J.P. et al, 1988, J. Biol. Chem. 263:10481- 10488; Saus, J. et al, 1988, J. Biol. Chem. 263:13374-13380; Gunwar, S. et al, 1990, J. Biol. Chem. 265:5466-5469; Gunwar S. et al, 1991, J. Biol. Chem. 266:15318-15324; Kahsai, T.Z. et al, 1997, J. Biol. Chem. 272:17023-17032).
  • Arresten Production of the recombinant form of Arresten is described in Neilson et al. (1993, J. Biol. Chem. 268:8402-8406).
  • the protein can also be expressed in 293 kidney cells (e.g., by the method described in Hohenester, E. et al, 1998, EMBO J. 17:1656-1664).
  • Arresten can also be isolated according to the method of Pihlajaniemi, T. et al. (1985, J. Biol. Chem. 260:7681-7687).
  • nucleotide (SEQ ID NO:l) and amino acid (SEQ ID NO:2) sequence of the ⁇ l chain of the NCI domain of Type IV collagen are shown in Fig. 1.
  • the approximate beginning and end of Arresten are marked.
  • Arresten generally comprises the NCI domain of the ⁇ l chain of Type IV collagen, and possibly also the junction region, which are the 12 amino acids immediately before the NCI domain.
  • Native Arresten was isolated from human placenta using bacterial collagenase, anion-exchange chromatography, gel filtration chromatography, HPLC, and affinity chromatography (Gunwar, S. et al, 1991, j. Biol. Chem. 266:15318-24; Weber, S. et al, 1984, Eur. j. Biochem. 139:401-10).
  • Type IV collagen monomers isolated from human placenta were HPLC-purified using a C-18 hydrophobic column (Pharmacia, Piscataway, New Jersey, USA). The constituent proteins were resolved with an acetonitrile gradient (32% - 39%). A major peak was visible, and a small double peak. SDS-PAGE analysis revealed two bands within the first peak, and no detectable proteins in the second peak. Immunoblotting, also found no immunodetectable protein in the second peak, and the major peak was identified as Arresten.
  • Example 2 Recombinant Production of Arresten in E. coli.
  • the sequence encoding Arresten was amplified by PCR from the ⁇ l NCl(IV)/pDS vector (Neilson, E.G. et al, 1993, J. Bio. Chem. 268:8402-5) using the forward primer 5'-CGG GAT CCT TCT GTT GAT CAC GGC TTC-3' (SEQ ID NO:3) and the reverse primer 5'-CCC AAG CTT TGT TCT TCT CAT ACA GAC- 3 ' (SEQ LD NO:4).
  • the resulting cDNA fragment was digested with Bam ⁇ I and HmdlLI and ligated into predigested pET22b(+) (Novagen, Madison, Wisconsin, USA). This construct is shown in Fig. 2.
  • HMS174 (Novagen, Madison, Wisconsin, USA) and then transformed into BL21 (Novagen, Madison, Wisconsin, USA) for expression.
  • An overnight bacterial culture was used to inoculate a 500 ml culture of LB medium. This culture was grown for approximately four hours until the cells reached an OD 600 of 0.6. Protein expression was then induced by addition of IPTG to a final concentration of 1 -2 M. After a two-hour induction, cells were harvested by centrifugation at 5000 x g and lysed by resuspension in 6 M guanidine, 0.1 M NaH 2 PO 4 , 0.01M Tris-HCl (pH 8.0).
  • Resuspended cells were sonicated briefly, and centrifuged at 12,000 x g for 30 minutes. The supernatant fraction was passed over a 5 ml Ni-NTA agarose column (Qiagen, Hilden, Germany) four to six times at a speed of 2 ml per minute. Non- specifically bound protein was removed by washing with both 10 mM and 25 mM imidazole in 8 M urea, 0.1 M NaH 2 PO 4 , 0.01 M Tris-HCl (pH 8.0).
  • Arresten protein was eluted from the column with increasing concentrations of imidazole (50 mM, 125 mM and 250 mM) in 8 M urea, 0.1 M NaH 2 PO 4 , 0.01 M Tris-HCl (pH 8.0). The eluted protein was dialyzed twice against PBS at 4 °C. A minor portion of the total protein precipitated during dialysis. Dialyzed protein was collected and centrifuged at approximately 3500 x g and separated into pellet and supernatant fractions. Protein concentration in each fraction was determined by the BCA assay (Pierce Chemical Co., Rockford, Illinois, USA) and quantitative SDS-PAGE analysis. The fraction of total protein in the pellet was approximately 22%), with the remaining 78% recovered as a soluble protein. The total yield of protein was approximately lO mg/liter.
  • the E. co/t-expressed protein was isolated predominantly as a soluble protein, and SDS-PAGE revealed a monomeric band at 29 kDa.
  • the additional 3 kDa arises from polylinker and histidine tag sequences and was irnmunodetected by both Arresten and 6-Histidine tag antibodies.
  • Example 3 Expression of Arresten in 293 Embryonic Kidney Cells.
  • the pDS plasmid containing ⁇ l(IN) ⁇ C1 was used to amplify Arresten in a way that it would add a leader signal sequence in- frame into the pcD ⁇ A 3.1 eukaryotic expression vector (InVitrogen, San Diego, California, USA).
  • the leader sequence from the 5' end of the full length ⁇ l(IV) chain was cloned 5' to the ⁇ C1 domain to enable protein secretion into the culture medium.
  • the Arresten- containing recombinant vectors were sequenced using flanking primers. Error-free cD ⁇ A clones were further purified and used for in vitro translation studies to confirm protein expression.
  • the Arresten-containing plasmid and control plasmid were used to transfect 293 cells using the calcium chloride method.
  • Transfected clones were selected by geneticin antibiotic treatment (Life Technologies/Gibco BRL, Gaithersburg, Maryland, USA). The cells were passed for three weeks in the presence of the antibiotic until no cell death was evident. Clones were then expanded into T-225 flasks and grown until confluent. The supernatant was then collected and concentrated using an amicon concentrator (Amicon). The concentrated supernatant was analyzed by SDS-PAGE, immunoblotting and ELISA for Arresten expression. Strong binding in the supernatant was detected by ELISA. SDS-PAGE analysis revealed a single major band at about 30 kDa.
  • Arresten- containing supernatant was subjected to affinity chromatography using Arresten- specific antibodies (Gunwar, S. et al, 1991, J. Biol. Chem. 266:15318-24). A major peak was identified, containing a monomer of about 30 kDa that was immunoreactive with Arresten antibodies. Approximately 1-2 mg of recombinant Arresten was produced per liter of culture fluid.
  • Example 4 Arresten Inhibits Endothelial Cell Proliferation.
  • C-PAE cells were grown to confluence in DMEM with 10% fetal calf serum (FCS) and kept contact inhibited for 48 hours.
  • Control cells were 786-0 (renal carcinoma) cells, PC-3 cells, HPEC cells, and A-498 (renal carcinoma) cells. Cells were harvested with trypsinization (Life Technologies/Gibco BRL, Gaithersburg, Maryland, USA) at 37°C for five minutes.
  • a suspension of 12,500 cells in DMEM with 1% FCS was added to each well of a 24-well plate coated with 10 ⁇ g/ml fibronectin. The cells were incubated for 24 hours at 37°C with 5% CO 2 and 95% humidity.
  • Figs. 3A and 3B are a pair of graphs showing incorporation of 3 H-thymidine into C-PAE cells treated with varying amounts of Arresten (Fig. 3 A) or endostatin (Fig. 3B).
  • Arresten appeared to inhibit thymidine incorporation in C-PAE as well as did endostatin.
  • Behavior of control cells treated with Arresten and endostatin is also shown in Fig. 4A, 4B, 4C, and 4D, with Arresten having little effect on 786-0 cells (Fig. 4A), PC-3 cells (Fig. 4B), or HPEC cells (Fig. 4C). Endostatin had little effect on A-498 cells (Fig. 4D). All groups in Figs. 3 and 4 represent triplicate samples.
  • Example 5 Arresten Inhibits Endothelial Cell Migration.
  • ECV-304 cells human umbilical endothelial cells
  • ATCC 1998-CRL American Type Culture Collection, 10801 University Boulevard, Manassas, VA, 20110-2209, USA
  • a Boyden chamber assay Neuro-Probe, Inc., Cabin John, Maryland, USA
  • ECV-304 cells were grown in M199 medium containing 10% FBS and 5 ng/mlDilC18(3) living fluorescent stain (Molecular Probes, Inc., Eugene, Oregon, USA) overnight.
  • M199 medium containing 2% FBS was placed in the lower chamber as a chemotactant.
  • the cell- containing compartments were separated from the chemotactant with polycarbonate filters (Poretics Corp., Livermore, California, USA) of 8 ⁇ m pore size.
  • the chamber was incubated at 37°C with 5% CO 2 and 95% humidity for 4.5 hours.
  • Example 6 Arresten Inhibits Endothelial Tube Formation.
  • matrigel Collaborative Biomedical Products, Bedford, Massachusetts, USA
  • the cells were treated with increasing concentrations of either Arresten, BSA, sterile PBS or the 7S domain. All assays were performed in rtiplicate.
  • the matrigel assay was also conducted in vivo in C57/BL6 mice. Matrigel was thawed overnight at 4°C. It was then mixed with 20U/ml of heparin (Pierce Chemical Co., Rockford, Illinois, USA), 150 ng/ml of bFGF (R&D Systems, Minneapolis, Minnesota, USA), and either 1 ⁇ g/ml of Arresten or 10 ⁇ g/ml of endostatin. The matrigel mixture was injected subcutaneously using a 21g needle. Control groups received the same mixture, but with no angiogenic inhibitor.
  • mice were sacrificed and the matrigel plugs removed.
  • the matrigel plugs were fixed in 4% paraformaldehyde in PBS for 4 hours at room temperature, then switched to PBS for 24 hours.
  • the plugs were embedded in paraffin, sectioned, and H&E stained. Sections were examined by light microscopy and the number of blood vessels from 10 high-power fields were counted and averaged.
  • Example 7 Arresten Inhibits Tumor Metastases in vivo.
  • C57/BL6 mice were intravenously injected with 1 million MC38/MUC1 (Gong, J. et al, 1997, Nat. Med. 3:558-61). Every other day for 26 days, five control mice were injected with 10 mM of sterile PBS, while six experimental mice received 4 mg/ml Arresten. After 26 days of treatment, pulmonary tumor nodules were counted for each mouse, and averaged for the two groups. Two deaths were recorded in each group. Arresten significantly reduced the average number of primary nodules from 300 in control mice, to 200.
  • Example 8 Arresten Inhibits Tumor Growth in vivo.
  • 786-0 cells Two million 786-0 cells were injected subcutaneously into 7- to 9-week-old male athymic nude mice. In the first group of six mice, the tumors were allowed to grow to about 700 mm 3 . In a second group of six mice, the tumors were allowed to group to 100 mm 3 . Arresten in sterile PBS was injected I.P. dailyfor 10 days, at a concentration of 20 mg/kg for the mice with tumors of 700 mm 3 , and 10 mg/kg for the mice with tumors of 100 mm . Control mice received either BSA or the PBS vehicle. The results are shown in Figs. 9A and 9B. Fig.
  • FIG. 9A is a plot showing the increase in tumor volume from 700 mm 3 for 10 mg/kg Arresten-treated (D), BSA- treated (+), and control mice (•). Tumors in the Arresten-treated mice shrank from 700 to 500 mm 3 , while tumors in BSA-treated and control mice grew to about 1200 mm 3 in 10 days.
  • Fig. 9B shows that in mice with tumors of 100 mm 3 , Arresten (D) also resulted in tumor shrinkage, to about 80 mm 3 , while BSA-treated tumors (+) increaed in size to nearly 500 mm in 10 days.
  • PC-3 cells human prostate adenocarcinoma cells
  • the tumors grew for 10 days, and were then measured with Vernier calipers.
  • the tumor volume was calculated using the standard formula (width x length x 0.52 (O'Reilly, M.S. et al, 1997, Cell 88:277-85; O'Reilly, M/S. et al, 1994, Cell 79:315-28). Animals were divided into groups of 5-6 mice. Experimental groups were injected I.P. daily with Arresten (10 mg/kg/day) or endostatin (10 mg/kg/day). The control group received PBS each day. The results are shown in Fig.
  • Native Arresten isolated from human placenta was injected intravenously into rate 200g in size. Each rat received 5 mg of human Arresten. Serum was analyzed by direct ELISA at different time points for the presence of circulating Arresten by use of anti- Arresten antibodies. As a control, serum albumin was also evaluated at each time point to ensure that identical amounts of serum were used for the analysis. Arresten was found to circulate in the serum with a half-life of about 36 hours.
  • Another group of rats were injected with 200 ⁇ g of human Arresten I.P. and/or subcutaneously, and evaluated for signs of disease pathogenesis in the lung, kidney, liver, pancreas, spleen, brain, testis, ovary, etc.
  • Direct ELISA was performed and Arresten antibodies were detected in the serum of these rats and some endogenous IgG deposition was noticed on the kidney glomerular basement membrane, as was observed previously (Kalluri, R. et al, 1994, Proc. Natl. Acad. Sci. USA 91 :6201-5).
  • the antibody deposition in the kidney was not accompanied by any signs of inflammation or deterioration of renal function.
  • Example 10 Binding and Inhibition of MMP-2 Enzyme by Arresten.
  • MMP-2, MMP-9, and antibodies to these enzymes were purchased from Oncogene, Inc. Direct ELISA was performed using native Arresten isolated from human placenta as described previously (Kalluri, R. et al, 1994, Proc. Natl. Acad. Sci. USA 91:6201-5). Both MMP-2 and MMP-9 specifically bound Arresten. They did not bind the 7S domain. This binding is independent of TIMP-2 and TIMP-1 binding, respectively.
  • Example 11 Recombinant Production of Canstatin in E. coli.
  • the nucleotide (SEQ ID ⁇ O:5) and amino acid (SEQ ID NO:6) sequence for the ⁇ 2 NCI domain of Type IV collagen is shown in Fig. 10.
  • the sequence encoding Canstatin was amplified by PCR from the ⁇ 2 NCI (IV)/pDS vector (Neilson, E.G. et al, 1993, J. Biol. Chem. 268:8402-5) using forward primer 5'- CGG GAT CCT GTC AGC ATC GGC TAC CTC-3' (SEQ ID NO:7) and reverse primer 5'-CCC AAG CTT CAG GTT CTT CAT GCA CAC-3' (SEQ LD NO:8).
  • the resulting cDNA fragment was digested with Bam ⁇ I and Htwdlll and ligated into predigested pET22b(+) (Novagen, Madison, Wisconsin, USA). The construct is shown in Fig. 11. This ligation placed Canstatin downstream of, and in- frame with, the pelB leader sequence, allowing for periplasmic localization and expression of soluble protein. Additional vector sequence was added to the protein encoding amino acids MDIGINSD (SEQ ID NO: 13). The 3' end of the sequence was ligated in-frame with the poly-histidine-tag sequence. Additional vector sequence between the 3' end of the cDNA and the his-tag encoded the amino acids KLAAALE (SEQ LD NO: 14). Positive clones were sequenced on both strands.
  • Plasmid constructs encoding Canstatin were first transformed into E. coli ⁇ MS174 (Novagen, Madison, Wisconsin, USA) and then transformed into BL21 for expression (Novagen, Madison, Wisconsin, USA). An overnight bacterial culture was used to inoculate a 500 ml culture in LB medium. This culture was grown for approximately 4 hours until the cells reached an OD 600 of 0.6. Protein expression was then induced by addition of IPTG to a final concentration of 0.5 mM. After a 2- hour induction, cells were harvested by centrifugation at 5,000 x g and lysed by resuspension in 6 M guanidine, 0.1 M NaH 2 PO 4 , 0.01 M Tris-HCl, pH 8.0.
  • Resuspended cells were sonicated briefly, and centrifuged at 12,000 x g for 30 minutes. The supernatant fraction was passed over a 5 ml Ni-NTA agarose column (Qiagen, Hilden, Germany) 4-6 times at a speed of 2 ml/min. Non-specifically bound protein was removed by washing with 15 ml each of 10 mM, 25 mM and 50 mM imidazole in 8 M urea, 0.1 M NaH 2 PO 4 , 0.01 M Tris-HCl, pH 8.0.
  • Canstatin protein was eluted from the column with two concentrations of imidazole (125 mM and 250 mM) in 8 M urea, 0.1 M NaH 2 PO 4 , 0.01 M Tris-HCl, pH 8.0. The eluted protein was dialyzed twice against PBS at 4°C. A portion of the total protein precipitated during dialysis. Dialyzed protein was collected and centrifuged at approximately 3,500 x g and separated into pellet and supernatant fractions. Protein concentration in each fraction was determined by the BCA assay (Pierce Chemical Co., Rockford, Illinois, USA) and quantitative SDS-PAGE analysis.
  • the SDS- PAGE analysis revealed a monomeric band at 29 kDa, with the additional 3 kDa arising from polylinker and histidine tag sequences.
  • the elutions containing Canstatin were combined and dialyzed against PBS for use in subsequent assays.
  • Canstatin protein analyzed by SDS-PAGE and Western blotting was detected by poly-histidine tag antibodies.
  • Collagen Type IV NCI antibodies also detected bacterially-expressed recombinant constantin protein.
  • the E. coli expressed protein was isolated predominantly as a soluble protein. The fraction of total protein in the pellet was approximately 40%, with the remaining 60% recovered as a soluble protein. The total yield of protein was approximately 15 mg/liter.
  • Example 12 Expression of Canstatin in 293 Embryonic Kidney Cells.
  • the pDS plasmid containing ⁇ 2(IV)NCl was used to PCR amplify Canstatin in such a way that a leader signal sequence would be added in-frame into the pcDNA 3.1 eukaryotic expression vector (InVitrogen, San Diego, California, USA).
  • the leader sequence from the 5' end of full length ⁇ 2(IN) chain was cloned 5' to the ⁇ C1 domain to enable protein secretion into the culture medium.
  • the Canstatin-containing recombinant vectors were sequenced using flanking primers.
  • Error free cD ⁇ A clones were further purified and used for in vitro translation studies to confirm protein expression.
  • the Canstatin-containing plasmid and control plasmid were used to transfect 293 cells using the calcium chloride method (Kingston, R.E., 1996, "Calcium Phosphate Transfection," pp. 9.1.4 - 9.1.7, in: Curent Protocols in Molecular Biology, Ausubel, F.M., et al, eds., Wiley and Sons, Inc. New York, New York, USA).
  • Transfected clones were selected by geneticin (Life Technologies/Gibco BRL, Gaithersberg, Maryland, USA) antibiotic treatment.
  • the cells were passed for three weeks in the presence of the antibiotic until no cell death was evident. Clones were expanded into T-225 flasks and grown until confluent. Then, the supernatant was collected and concentrated using an amicon concentrator (Amicon, Inc.). The concentrated supernatant was analyzed by SDS-PAGE, immunoblotting and ELISA for Canstatin expression. Strong binding in the supernatant was detected by ELISA. Canstatin- containing supernatant was subjected to affinity chromatography using Canstatin specific antibodies (Gunwar, S. et al, 1991, J. Biol. Chem. 266:15318-24). A major peak was identified, containing a pure monomer of about 24 kDa that was immunoreactive with Canstatin antibodies (anti- ⁇ 2 NCI antibody, 1:200 dilution).
  • Example 13 Canstatin Inhibits Endothelial Cell Proliferation.
  • Bovine calf aortic endothelial (CP AE) cells were grown to confluence in DMEM with 10% fetal calf serum (FCS) and kept contact inhibited for 48 hours. Cells were harvested by trypsinization (Life Technologies/ Gibco BRL, Gaithersberg, Maryland, USA) at 37°C for 5 minutes. A suspension of 12,500 cells in DMEM with 0.5 % FCS was added to each well of a 24-well plate coated with 10 ⁇ g/ml fibronectin. The cells were incubated for 24 hours at 37°C with 5% CO 2 and 95%) humidity. Medium was removed, and replaced with DMEM containing 0.5 % FCS (unstimulated) or 10 % FCS (stimulated and treated cells).
  • FCS fetal calf serum
  • 786-0, PC-3 and HEK 293 cells served as controls and were also grown to confluency, trypsinized and plated in the same manner. Cells were treated with concentrations of Canstatin or endostatin ranging from 0.025 to 40 mg/ml in triplicate.
  • thymidine incorporation experiments all wells received 1 mCurie of 3 H-thymidine at the time of treatment. After 24 hours, medium was removed and the wells were washed 3 times with PBS. Radioactivity was extracted with IN NaOH and added to a scintillation vial containing 4 ml of ScintiVerse II (Fisher Scientific, Pittsburgh, Pennsylvania, USA) solution. Thymidine incorporation was measured using a scintillation counter.
  • Fig. 12A is a histogram showing the effect of varying amounts of Canstatin on the proliferation of CP AE cells. Thymidine incorporation in counts per minute is on the y-axis. "0.5%" on the x-axis is the 0.5% FCS (unstimulated) control, and "10%” is the 10% FCS (stimulated) control. Treatment with increasing concentrations of Canstatin steadily reduced thymidine incorporation.
  • Fig. 12B is a histogram showing the effect of increasing amounts of Canstatin on thymidine incorporation in the nonendothelial cells 786-0, PC-3 and HEK 293.
  • Thymidine incorporation in counts per minute is show in the y-axis, and the x-axis shows, for each of the three cell lines, the 0.5% FCS (unstimulated) and the 10% FCS (stimulated) control, followed by increasing concentrations of Canstatin. All groups represent triplicate samples, and the bars represent mean counts per minute ⁇ the standard error of the mean.
  • a methylene blue staining test was also done. 3,100 cells were added to each well and treated as above, and cells were then counted using the method of Oliver et al. (Oliver, M.H. et al, 1989, J. Cell. Science 92:513-8). All wells were washed one time with 100 ml of IX PBS and the cells were fixed by adding 100 ml of 10% formalin in neutral-buffered saline (Sigma Chemical Co., St. Louis, Missouri, USA) for 30 minutes at room temperature. After formalin removal cells were stained with a solution of 1% methylene blue (Sigma Chemical Co., St. Louis, Missouri, USA) in 0.01 M borate buffer (pH 8.5) for 30 minutes at room temperature.
  • Figs. 12C and 12D are histogram showing the effect of increasing amounts of Canstatin on the uptake of dye by CPAE cells. Absorbance at OD 655 is shown on the y-axis.
  • 0.1% represents the 0.1% FCS-treated (unstimulated) control
  • 10% is the 10% FCS-treated (stimulated) control.
  • the remaining bars represent treatments with increasing concentrations of Canstatin.
  • dye uptake dropped off to the level seen in unstimulated cells at a Canstatin treatment level of about 0.625 - 1.25 ⁇ g/ml.
  • Fig. 12D is a histogram showing the effect of varying concentrations of Canstatin on non-endothelial cells HEK 293 (white bars) and PC-3 (cross-hatched bars). Absorbance at OD 655 is on the y-axis.
  • Figs. 12A and 12C A dose-dependent inhibition of 10% serum-stimulated endothelial cells was detected with an ED 50 value of approximately 0. 5 ⁇ g/ml (Figs. 12A and 12C). No significant effect was observed on the proliferation of renal carcinoma cells (786-0), prostate cancer cells (PC-3) or human embryonic kidney cells (HEK293), at Canstatin doses up to 40 mg/ml (Figs. 12B and 12D). This endothelial cell specificity indicates that Canstatin is likely a particularly effective anti-angiogenic agent.
  • Example 14 Canstatin Inhibits Endothelial Cell Migration.
  • M199 containing 0.5% FBS After trypsinizing, washing and diluting cells in M199 containing 0.5% FBS, 60,000 cells were seeded in the upper chamber wells, together with or without Canstatin (0.01 or 1.00 mg/ml). Ml 99 medium containing 2% FBS was placed in the lower chamber as a chemotactant. The cell-containing compartments were separated from the chemotactant with polycarbonate filters (Poretics Corp., Livermore, California, USA) of 8 ⁇ m pore size. The chamber was incubated at 37 °C with 5% CO 2 and 95%) humidity for 4.5 hours.
  • polycarbonate filters Poretics Corp., Livermore, California, USA
  • Fig. 13 is a bar chart showing the number of migrated endothelial cells per field (y-axis) for treatments of no VEGF (no VEGF or serum), and VEGF (1% FCS and 10 ng/ml VEGF) cells, and for treatments of 0.01 Canstatin (1% FCS and 10 ng/ml VEGF and 0.01 ⁇ g/ml Canstatin) and 1.0 ⁇ g/ml Canstatin (1% FCS and 10 ng/ml VEGF and 1 ⁇ g/ml Canstatin).
  • Canstatin inhibited the migration of HUVECs with a significant effect observed at 10 ng/ml.
  • the ability of Canstatin to inhibit both proliferation and migration of endothelial cells suggests that it works at more than one step in the process of angiogenesis.
  • Canstatin may act as an apoptotic signal for stimulated endothelial cells which would be able to affect both proliferation and migration.
  • Apoptotic induction has been reported for angiostatin, another anti- angiogenic molecule (O'Reilly, M.S. et al, 1994, Cell 79:315-28; Lucas, R. et al, 1998, Blood 92:4730-41).
  • Example 15 Canstatin Inhibits Endothelial Tube Formation.
  • Canstatin's anti-angiogenic capacity As a first test of Canstatin's anti-angiogenic capacity, it was assessed for its ability to disrupt tube formation by endothelial cells in matrigel, a solid gel of mouse basement membrane proteins. When mouse aortic endothelial cells are cultured on matrigel, they rapidly align and form hollow tube-like structures.
  • Matrigel (Collaborative Biomedical Products, Bedford, Massachusetts, USA) was added (320 ml) to each well of a 24 well plate and allowed to polymerize (Grant, D.S. et al, 1994, Pathol. Res. Pract. 190:854-63).
  • a suspension of 25,000 mouse aortic endothelial cells (MAE) in EGM-2 (Clonetics Co ⁇ oration, San Diego, California, USA) medium without antibiotic was passed into each well coated with matrigel.
  • the cells were treated with either Canstatin, BSA, sterile PBS or ⁇ 5-NCl domain in increasing concentrations. All assays were performed in triplicate.
  • Example 16 Canstatin Inhibits Tumor Growth In Vivo.
  • PC-3 cells Human prostate adenocarcinoma cells
  • mice Human prostate adenocarcinoma cells
  • mice were harvested from culture and 2 million cells in sterile PBS were injected subcutaneously into 7- to 9- week-old male SCLD mice.
  • the tumors grew for approximately 4 weeks after which animals were divided into groups of 4 mice.
  • Experimental groups were injected daily I.P. with Canstatin at a dosage of 10 mg/kg in a total volume of 0.1 ml of PBS.
  • the control group received equal volumes of PBS each day.
  • the tumors ranged in volume from 88 mm to 135 mm for the control mice, andl08 mm 3 to 149 mm 3 for the Canstatin-treated mice.
  • Each group contained 5 mice.
  • Fig. 15 A is a graph depicting the fractional tumor volume (y-axis) ⁇ the standard error, plotted over the treatment day (x-axis).
  • PC-3 cells were harvested from culture and 3 million cells were injected into 6- to 7-week-old old athymic nude mice, and tumors were allowed to grow subcutaneously for approximately 2 weeks after which the animals were divided into groups of 4 mice.
  • Experimental groups (4 mice) were injected daily I.P. with Canstatin at a dosage of 3 mg/kg in a total volume of 0.2 ml of PBS or endostatin at a dosage of 8 mg/kg in the same volume of PBS.
  • the control group (4 mice) received equal volumes of PBS each day. Tumor length and width were measured using a Vernier caliper and the tumor volume was calculated using the standard formula: length x width 2 x 0.52.
  • Fig. 15B is a graph depicting the fractional tumor volume (y-axis) ⁇ the standard error, plotted over the treatment day (x-axis).
  • D Relative to controls
  • Canstatin-treated ( ⁇ ) tumors increased only marginally in size, and the results compared favorably with those achieved with endostatin (O).
  • O endostatin
  • the tumors were allowed to grow to either about 100 mm 3 or about 700 mm 3 .
  • Each group contained 6 mice.
  • Canstatin in sterile PBS was injected I.P. daily at a concentration of 10 mg/kg for 10 days.
  • the control group received the same volume of PBS.
  • the results are shown in Figs. 15C (100 mm 3 tumors) and 31D (700 mm 3 tumors). In both groups, the Canstatin-treated ( ⁇ ) tumors actually shrank relative to the controls (D).
  • Canstatin produced in E. coli inhibited the growth of small (100 mm 3 , Fig. 15C) and large (700 mm 3 , Fig. 15D) renal cell carcinoma (786-0) tumors.
  • PC-3 severe combined immunodeficient mice
  • Canstatin at 10 mg/kg held the fractional tumor volume to 55% of the vehicle only- injected mice.
  • athymic (nu/nu) mice lower doses of both Canstatin and endostatin were used, and 3 mg/kg of Canstatin had the same suppressive effect as 8 mg/kg of endostatin.
  • Example 17 CD31 Immunohistochemistry on Canstatin-Treated Mice.
  • the decreased size of the tumors in vivo suggested a suppressive effect on the formation of blood vessels in these tumors.
  • anti- CD31 antibody alkaline phosphatase-conjugated immunocytochemistry was performed on paraffin-embedded tumor sections. The removed tumors were dissected with a scapel into several pieces approximately 3 - 4 mm thick then fixed in 4% paraformaldehyde for 24 hours. Tissues were then switched to PBS for 24 hours before dehydration and parffin embedding. After embedding in paraffin, 3 mm tissue sections were cut and mounted. Sections were deparaffmized, rehydrated, and pretreated with 300 mg/ml protease XXIV (Sigma Chemical Co., St.
  • Example 18 Recombinant Production of Tumstatin and Tumstatin Mutants in E. coli.
  • the nucleotide (SEQ LD NO: 9) and amino acid (SEQ ID NO: 10) sequences for the ⁇ 3 chain of the NCI domain of Type IV collagen are shown in Fig. 16.
  • the sequence encoding Tumstatin was amplified by PCR from the ⁇ 3 NCI (IV)/pDS vector (Neilson, E.G. et al, 1993, J. Biol. Chem. 268:8402-5) using the forward primer 5'-CGG GAT CCG GGT TTG AAA GGA AAA CGT-3' (SEQ ID NO:l 1) and the reverse primer 5'- CCC AAG CTT TCA GTG TCT TTT CTT CAT-3' (SEQ ID NO: 12).
  • the resulting cDNA fragment was digested with Bam ⁇ l and Hzndlll and ligated into predigested pET22b(+) (Novagen, Madison, Wisconsin, USA). The construct is shown in Fig. 17.
  • the ligation placed Tumstatin downstream of and in- frame with the pelB leader sequence, allowing for periplasmic localization and expression of soluble protein.
  • Additional vector sequence was added to the protein encoding amino acids MDIGINSD (SEQ ID NO: 13). The 3' end of the sequence was ligated in-frame with the poly-histidine-tag sequence. Additional vector sequence between the 3' end of the cDNA and the his-tag encoded the amino acids KLAAALE (SEQ LD NO: 14).
  • Plasmid constructs encoding Tumstatin were first transformed into E. coli HMS174 (Novagen, Madison, Wisconsin, USA) and then transformed into BL21 for expression (Novagen, Madison, Wisconsin, USA). Overnight bacterial culture was used to inoculate a 500 ml culture in LB medium (Fisher Scientific, Pittsburgh, Pennsylvania, USA). This culture was grown for approximately 4 hours until the cells reached an OD 600 of 0.6. Protein expression was then induced by addition of IPTG to a final concentration of 1 mM.
  • cells were harvested by centrifugation at 5,000 x g and lysed by resuspension in 6 M guanidine, 0.1 M NaH 2 PO 4 , 0.01 M Tris-HCl, pH 8.0. Resuspended cells were sonicated briefly, and centrifuged at 12,000 x g for 30 minutes. The supernatant fraction was passed over a 5 ml Ni-NTA agarose column (Qiagen, Hilden, Germany) 4-6 times at a speed of 2 ml per minute.
  • Non-specifically bound protein was removed by washing with both 10 mM and 25 mM imidazole in 8 M urea, 0.1 M NaH 2 PO 4 , 0.01 M Tris-HCl, pH 8.0.
  • Tumstatin protein was eluted from the column with increasing concentrations of imidazole (50 mM, 125 mM, and 250 mM) in 8 M urea, 0.1 M NaH 2 PO 4 , 0.01 M Tris-HCl, pH 8.0.
  • the eluted protein was dialyzed twice against PBS at 4°C. A portion of the total protein precipitated during dialysis. Dialyzed protein was collected and centrifuged at approximately 3,500 x g and separated into insoluble (pellet) and soluble (supernatant) fractions.
  • Tumstatin was isolated predominantly as a soluble protein and SDS-PAGE analysis revealed a monomeric band at 31 kDa. The additional 3 kDa arises from polylinker and histidine tag sequences. The eluted fractions containing this band were used in following experiments. Protein concentration in each fraction was determined by the BCA assay (Pierce Chemical Co., Rockford, Illinois, USA) and quantitative SDS-PAGE analysis using scanning densitometry. Under reducing conditions, a band observed around 60 kDa representing a dimer of tumstatin in non-reduced condition resolved as a single band of 31 kDa. The total yield of protein was approximately 5 mg per liter.
  • Tumstatin-N53 Recombinant truncated Tumstatin (Tumstatin-N53) lacking the 53 N- terminal amino acids was produced in E. coli and purified as previously described for another mutant (Kalluri, R. et al, 1996, J. Biol. Chem. 271:9062-8).
  • This mutant is depicted in Fig. 18, which is a composite diagram showing the location of truncated amino acids within the ⁇ 3(IV) NCI monomer. The filled circles correspond to the N-terminal 53 amino acid residues deleted from Tumstatin to generate Tumstatin-N53' (Kalluri, R. et al, 1996, J. Biol. Chem. 271 :9062-8).
  • the disulfide bonds are arranged as they occur in ⁇ l(IV) NCI and ⁇ 2(JN) ⁇ C1 (Siebold, B. et al, 1988, ⁇ ur. J. Biochem. 176:617-24). For clarity, only one of two possible disulfide configurations is indicated.
  • Rabbit antibodies raised against human ⁇ 3 (IV) ⁇ C1 were prepared as previously described (Kalluri, R. et al, 1997, J. Clin. Invest. 99:2470-8).
  • Monoclonal rat anti-mouse CD31 platelet endothelial cell adhesion molecule, P ⁇ CAM-1) antibody was purchased from (PharMingen, San Diego, California, USA).
  • FITC-conjugated goat anti-rat IgG antibody, FITC-conjugated goat anti- rabbit IgG antibody, and goat anti rabbit IgG antibody conjugated with horseradish peroxidase were purchased from Sigma Chemical Co. (St. Louis, Missouri, USA).
  • the concentrated supernatant obtained above was analyzed by SDS-PAGE and immunoblotting for the Tumstatin expression as previously described (Kalluri, R. et al, 1996, J. Biol. Chem. 271 :9062-8).
  • SDS-PAGE in one dimension was carried out with 12% resolving gels and the discontinuous buffer system.
  • the separated proteins were transferred to nitrocellulose membrane and blocked with 2% BSA for 30 minutes at room temperature. After blocking the remaining binding sites, the membrane was washed thoroughly with wash buffer and incubated with a primary antibody at a dilution of 1 : 1000 in PBS containing 1% BSA. Incubation was carried out at room temperature overnight on a shaker.
  • the blot was then washed thoroughly with washing buffer and incubated with a secondary antibody conjugated to horseradish peroxidase for 3 hours at room temperature on a shaker.
  • the blot was again washed thoroughly and substrate (diaminobenzidine in 0.05 M phosphate buffer containing 0.01% cobalt chloride and nickel ammonium) was added and incubated for 10 minutes at room temperature.
  • substrate diaminobenzidine in 0.05 M phosphate buffer containing 0.01% cobalt chloride and nickel ammonium
  • the substrate solution was then poured out, and substrate buffer containing hydrogen peroxide was added. After development of bands, the reaction was stopped with distilled water and the blot was dried. A single band of 31 kDa was seen.
  • Example 19 Expression of Tumstatin in 293 Embryonic Kidney Cells.
  • Human tumstatin was also produced as a secreted soluble protein in 293 embryonic kidney cells using the pcDNA 3.1 eukaryotic vector. This recombinant protein (without any purification or detection tags) was isolated using affinity chromatography and a pure monomeric form was detected in the major peak by SDS-PAGE and immunoblot analyses.
  • the pDS plasmid containing ⁇ 3(IV)NCl was used to PCR amplify Tumstatin in a way that it would add a leader signal sequence in-frame into the pcDNA 3.1 eukaryotic expression vector (InVitrogen, San Diego, California, USA).
  • the leader sequence from the 5' end of full length ⁇ 3(LV) chain was cloned 5' to the NCI domain to enable protein secretion into the culture medium.
  • the Tumstatin-containing recombinant vectors were sequenced on both strands using flanking primers.
  • Error-free cDNA clones were further purified and used for in vitro translation studies to confirm protein expression.
  • the Tumstatin-containing plasmid and control plasmid were used to transfect 293 cells using the calcium chloride method (Sambrook, J. et al, 1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, USA, pps. 16.32-16.40).
  • Transfected clones were selected by geneticin (Life Technologies/Gibco BRL, Gaithersburg, Maryland, USA) antibiotic treatment. The cells were passed for three weeks in the presence of the antibiotic until no cell death was evident. Clones were expanded into T-225 flasks and grown until confluent.
  • the supernatant was then collected and concentrated using an amicon concentrator (Amicon, Inc., Beverly, Massachusetts, USA).
  • the concentrated supernatant was analyzed by SDS-PAGE, immunoblotting and ELISA for the Tumstatin expression. Strong binding in the supernatant was detected by ELISA.
  • Tumstatin-containing supernatant was subjected to affinity chromatography and immunodetected with both anti-tumstatin and anti-6-Histidine tag antibodies (Gunwar, S. et al, 1991, J. Biol. Chem. 266:15318-24). A major peak was identified, containing a monomer of about 31 kDa that was immunoreactive with Tumstatin antibodies.
  • Example 20 Tumstatin Inhibits Endothelial Cell Proliferation.
  • 786-0 renal clear cell carcinoma line
  • PC-3 human prostate adenocarcinoma cell line
  • C-PAE bovine pulmonary arterial endothelial cell line
  • MAE mouse aortic endothelial cell line
  • C-PAE cells were grown to confluence in DMEM with 10% FCS and kept contact-inhibited for 48 hours. C-PAE cells were used between the second and fourth passages. 786-0 and PC-3 cells were used as non-endothelial controls in this experiment. Cells were harvested by trypsinization (Life Technologies/ Gibco BRL, Gaithersberg, Maryland, USA) at 37° C for 5 minutes. A suspension of 12,500 cells in DMEM with 0.1% FCS was added to each well of a 24-well plate coated with 10 ⁇ g/ml fibronectin. The cells were incubated for 24 hours at 37°C with 5% CO 2 and 95% humidity. Medium was removed and replaced with DMEM containing 20% FCS.
  • Unstimulated control cells were incubated with 0.1%) FCS.
  • Cells were treated with various concentrations of Tumstatin ranging from 0.01 to 10 mg/ml. All wells received 1 mCurie of 3 H-thymidine 12 hours after the beginning of treatment. After 24 hours, medium was removed and the wells were washed with PBS three times. Cells were extracted with IN NaOH and added to a scintillation vial containing 4 ml of ScintiVerse II (Fisher Scientific, Pittsburgh, Pennsylvania, USA) solution. Thymidine inco ⁇ oration was measured using a scintillation counter.
  • Figs. 19A, 19B and 19C are histograms showing 3 H-thymidine inco ⁇ oration (y-axis) for C-PAE cells (Fig. 19 A), PC-3 cells (Fig. 19B) and 786-0 cells (Fig. 19C) when treated with varying concentrations of Tumstatin (x-axis). All groups represent triplicate samples. Tumstatin significantly inhibited 20% FCS stimulated 3 H-thymidine inco ⁇ oration in a dose dependent manner with an ED 50 of approximately 0.01 mg/ml (Fig. 19A).
  • Example 21 Tumstatin Inhibits Endothelial Tube Formation.
  • Matrigel (Collaborative Biomedical Products, Bedford, Massachusetts, USA) was added (320 ml) to each well of a 24-well plate and allowed to polymerize (Grant, D.S. et al, 1994, Pathol. Res. Pract. 190:854-63).
  • the cells were treated with either Tumstatin, BSA or 7S domain in increasing concentrations. Control cells were incubated with sterile PBS. All assays were performed in triplicate.
  • Fig. 20 The results are shown in Fig. 20.
  • mouse aortic endothelial cells When mouse aortic endothelial cells are cultured on matrigel, a solid gel of mouse basement membrane proteins, they rapidly align and form hollow tube-like structures (Haralabopoulos, G.C. et al, 1994, Lab. Invest. 71:575-82).
  • Tumstatin produced in 293 cells, significantly inhibited endothelial tube formation in MAE cells in a dose dependent manner as compared to BSA controls (Fig. 20). Percentage of tube formation after treatment with 1 mg/ml of protein was, BSA 98.0 ⁇ 4.0, tumstatin 14.0 ⁇ 4.0. Similar results were also obtained using E. coli produced tumstatin.
  • the 7S domain of type IV collagen had no effect on endothelial tube formation. Maximum inhibition with tumstatin was attained between 800-1000 ng/ml. The difference between the mean percentage value of Tumstatin-treated (•, 0.1-10 mg/ml) and control (BSA (D), 7S domain (O)) was significant (PO.05). Each point represents the mean ⁇ SE of triplicate wells. This experiment was repeated three times. Data points marked by an asterisk were significant, with P ⁇ 0.05 by one tailed Student's t test. Well-formed tubes were observed in the 7S domain treatments. MAE cells treated with 0.8 mg/ml Tumstatin exhibiting decreased tube formation.
  • Matrigel Collaborative Biomedical Products, Bedford, Massachusetts, USA was thawed overnight at 4°C. Before injection into C57/BL6 mice, it was mixed with 20 U/ml of heparin (Pierce Chemical Co., Rockford, Illinois, USA), 150 ng/ml of bFGF (R&D Systems, Minneapolis, Minnesota, USA), and 1 mg/ml of Tumstatin. Control groups received no angiogenic inhibitor. The Matrigel mixture was injected sub-cutaneously using a 21 gauge needle. After 14 days, mice were sacrificed and the Matrigel plugs were removed.
  • Matrigel plugs were fixed in 4% para-formaldehyde (in PBS) for 4 hours at room temperature, then switched to PBS for 24 hours.
  • the plugs were embedded in paraffin, sectioned, and H & E stained. Sections were examined by light microscopy and the number of blood vessels from 10 high power fields were counted and averaged. All sections were coded and observed by a pathologist who was unaware of the study protocols.
  • Example 22 Tumstatin and Tumstatin Mutant Inhibit Tumor Growth In Vivo.
  • mice Five million PC-3 cells were harvested and injected subcutaneously on the back of 7- to 9-week-old male athymic nude mice. The tumors were measured using Vernier calipers and the volume was calculated using the standard formula width 2 x length x 0.52. The tumors were allowed to grow to about 100 mm 3 , and animals were then divided into groups of 5 or 6 mice. Tumstatin or mouse endostatin was intraperitoneally injected daily (20 mg/kg) for 10 days in sterile PBS to their respective experimental group. The control group received vehicle injection (either BSA or PBS). Tumor volume was calculated every 2 or 3 days over 10 days. The results are shown in Fig.
  • FIG. 21 A which is a graph showing tumor volume in mm 3 (y- axis) against days of treatment (x-axis) for the PBS control (D), 20 mg/kg Tumstatin (•) and 20 mg/kg endostatin (O).
  • Tumstatin produced in E. coli, significantly inhibited the growth of PC-3 human prostate tumors (Fig. 21 A).
  • Tumstatin at 20 mg/Kg inhibited tumor growth similar to endostatin at 20 mg/kg (Fig. 21 A).
  • Significant inhibitory effect on tumor growth was observed on day 10 (control 202.8 ⁇ 50.0 mm 3 , tumstatin 82.9 ⁇ -25.2 mm 3 , endostatin 68.9 ⁇ 16.7 mm 3 ).
  • Daily intraperitoneal injection of Tumstatin or endostatin inhibited the growth of human prostate adenocarcinoma cell (PC-3) tumor as compared to the control. This experiment was started when the tumor volumes were less than 100 mm .
  • Tumstatin's effect on another established primary tumors in mice was also studied. Two million 786-0 renal cell carcinoma cells were injected subcutaneously on the back of 7- to 9-week-old male athymic nude mice. The tumors were allowed to grow to about 600 to about 700 mm 3 and animals were then divided into groups of 6. Tumstatin was intraperitoneally injected daily (6 mg/kg) for 10 days in sterile PBS. The control group received BSA injections. The results are shown in Fig. 21B, which is a graph showing tumor volume in mm 3 (y-axis) against days of treatment (x-axis) for the PBS control (D) and for 6 mg/kg Tumstatin (•). E.
  • a portion of the NCI domain of the ⁇ 3 chain of type IV collagen ( ⁇ 3 (IN) ⁇ C1) is the pathogenic epitope of Goodpasture syndrome (Butkowski, R.J. et al, 1987, J. Biol. Chem. 262:7874-7; Saus, J. et al, 1988, J. Biol. Chem. 263:13374-80; Kalluri, R. et al, 1991, J. Biol. Chem. 266:24018-24).
  • Goodpasture syndrome is an autoimmune disease characterized by pulmonary hemorrhage and/or rapidly progressing glomerulonephritis (Wilson, C. & F. Dixon, 1986, The Kidney, W.B.
  • mice Two million 786-0 renal cell carcinoma cells were injected subcutaneously on the back of 7- to 9-week-old male athymic nude mice. The tumors were allowed to grow to a size of about 100-150 mm 3 . The mice were then divided into groups of 5, and were injected daily intraperitoneally with 20 mg/kg of the E. cob-expressed truncated Tumstatin lacking the 53 N-terminal amino acids (Kalluri, R. et al, 1996, J. Biol. Chem. 271:9062-8) for 10 days. Control mice received PBS injection. The results are shown in Fig.
  • Kidney and skin tissue from a 7-week-old male C57/BL6 mouse was processed for evaluation by immunofiuorescence microscopy.
  • the tissue samples were frozen in liquid nitrogen, and sections 4 mm thick were used.
  • Tissue was processed by indirect immunofiuorescence technique as previously described
  • Fig. 23 shows that the endothelial tube assay, performed as described above, the two Arresten fragments (12 kDa ( ⁇ ) and 8 kDa (D)) and the Canstatin fragment (19 kDa (A)) inhibited the formation of endothelial tubes to an even greater extent than did Arresten (•) or Canstatin (O).
  • Fig. 24 shows that the Tumstatin fragments, "333" (•) and "334" (O) likewise outperformed Tumstatin (A), with BSA ( ⁇ ) and the ⁇ 6 chain (D) serving as controls.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

L'invention se rapporte à des protéines présentant des propriétés anti-angiogéniques ainsi qu'à des méthodes d'utilisation de ces protéines pour inhiber l'angiogenèse.
PCT/US1999/013737 1998-06-17 1999-06-17 Proteines anti-angiogeniques et methodes d'utilisation de ces proteines WO1999065940A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
IL14023999A IL140239A0 (en) 1998-06-17 1999-06-17 Anti-angiogenic proteins and methods of use thereof
EP99928762A EP1086129A1 (fr) 1998-06-17 1999-06-17 Proteines anti-angiogeniques et methodes d'utilisation de ces proteines
JP2000554765A JP2002517999A (ja) 1998-06-17 1999-06-17 抗血管形成タンパク質およびその使用方法
CA002331332A CA2331332A1 (fr) 1998-06-17 1999-06-17 Proteines anti-angiogeniques et methodes d'utilisation de ces proteines
AU45755/99A AU753249B2 (en) 1998-06-17 1999-06-17 Anti-angiogenic proteins and methods of use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8968998P 1998-06-17 1998-06-17
US60/089,689 1998-06-17
US12617599P 1999-03-25 1999-03-25
US60/126,175 1999-03-25

Publications (1)

Publication Number Publication Date
WO1999065940A1 true WO1999065940A1 (fr) 1999-12-23

Family

ID=26780845

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/013737 WO1999065940A1 (fr) 1998-06-17 1999-06-17 Proteines anti-angiogeniques et methodes d'utilisation de ces proteines

Country Status (8)

Country Link
EP (1) EP1086129A1 (fr)
JP (3) JP2002517999A (fr)
KR (1) KR100682666B1 (fr)
CN (1) CN1309663A (fr)
AU (1) AU753249B2 (fr)
CA (1) CA2331332A1 (fr)
IL (1) IL140239A0 (fr)
WO (1) WO1999065940A1 (fr)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001051523A2 (fr) * 2000-01-07 2001-07-19 Beth Israel Deaconess Medical Center Proteines et fragments de proteines anti-angiogeniques et leurs procede d'utilisation
WO2001059112A1 (fr) * 2000-02-10 2001-08-16 Zymogenetics, Inc. Peptides intestinaux anti-angiogeniques, zdint5
WO2002012281A2 (fr) 2000-08-03 2002-02-14 Johns Hopkins University Vaccin moleculaire liant un polypeptide chaperon du reticulum endoplasmique a un antigene
US6358735B1 (en) 1995-06-30 2002-03-19 University Of Kansas Medical Center Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagen
US6361994B1 (en) 1995-06-30 2002-03-26 University Of Kansas Medical Center Method for inhibiting angiogenesis and tumors with the isolated NC1 α1 chain monomer of type IV collagen
WO2002083072A2 (fr) * 2001-04-13 2002-10-24 Boyce Thompson Institute For Plant Research Methodes et compositions pour medicaments stables a base de plantes transgeniques et leur utilisation comme contraceptifs
US6759047B1 (en) 1998-06-17 2004-07-06 Beth Israel Deaconess Hospital Corp. Anti-angiogenic proteins and methods of use thereof
US6962974B1 (en) 1998-06-17 2005-11-08 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
US7175840B2 (en) 2001-01-05 2007-02-13 Viromed Co., Ltd. Compositions for gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof
US7387779B2 (en) 1998-06-17 2008-06-17 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
CN100447155C (zh) * 2001-05-23 2008-12-31 中国科学院上海上海生命科学研究院 具有抑制内皮细胞生长活性的重组人内皮生长抑制蛋白
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
US20140179612A1 (en) * 2011-08-17 2014-06-26 The Regents Of The University Of Colorado, A Body Corporate Transferrin-Tumstatin Fusion Protein and Methods For Producing and Using the Same
US9011866B2 (en) 2005-01-06 2015-04-21 The Johns Hopkins University RNA interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by DNA and transfected dendritic cell vaccines
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US9701725B2 (en) 2003-05-05 2017-07-11 The Johns Hopkins University Anti-cancer DNA vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
CN111087477A (zh) * 2020-01-03 2020-05-01 四川大学华西医院 GBM-7S(α1)-NC1(α3)融合蛋白及其制备方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04000204A (es) * 2001-07-27 2004-03-18 Univ Kansas Medical Center Estructura cristalizada de colageno tipo iv del hexamero de dominio nc1.
JP4843767B2 (ja) * 2005-08-31 2011-12-21 国立大学法人 岡山大学 がん細胞特異的遺伝子発現法を用いた血管新生阻害薬
CN101962404A (zh) * 2010-06-17 2011-02-02 中国热带农业科学院热带生物技术研究所 一种用于治疗血管瘤的蛋白质
JP2016520053A (ja) * 2013-05-06 2016-07-11 中国▲薬▼科大学Ｃｈｉｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｕｎｉｖｅｒｓｉｔｙ 腫瘍微小環境における血管再生の抑制及び適応免疫応答の活性化を有する二機能の融合タンパク質及びその遺伝子並びに使用
CN113735966B (zh) * 2021-09-29 2022-11-01 陕西巨子生物技术有限公司 一种抗肿瘤重组胶原蛋白及其制备方法和应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989003392A1 (fr) * 1987-10-08 1989-04-20 Regents Of The University Of Minnesota Polypeptides ayant une activite de collagene de type iv
WO1991009113A1 (fr) * 1989-12-14 1991-06-27 Regents Of The University Of Minnesota Polypetptide synthetique a activite de collagene de type iv
WO1991008755A1 (fr) * 1989-12-14 1991-06-27 Regents Of The University Of Minnesota Polypeptide presentant une activite d'adherence, de propagation et de motilite de cellules de collagene de type iv
US5114840A (en) * 1989-07-07 1992-05-19 Karl Tryggvason Method for determining the nucleotide sequence of a novel α5(IV) chain of human type IV collagen
US5424408A (en) * 1990-11-30 1995-06-13 Yale University α-3 chain type IV collagen polynucleotides
WO1996000582A1 (fr) * 1994-06-30 1996-01-11 University Of Kansas Medical Center Utilisation de domaines isoles du collagene de type iv pour modifier les interactions cellulaires et tissulaires
US5593900A (en) * 1989-07-07 1997-01-14 Tryggvason; Karl Immunological methods for the detection of the human type IV collagen α5 chain
US5731192A (en) * 1993-08-27 1998-03-24 Yale University Collagen COL4A6: gene, protein and method of detecting collagen deficiency

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989003392A1 (fr) * 1987-10-08 1989-04-20 Regents Of The University Of Minnesota Polypeptides ayant une activite de collagene de type iv
US5114840A (en) * 1989-07-07 1992-05-19 Karl Tryggvason Method for determining the nucleotide sequence of a novel α5(IV) chain of human type IV collagen
US5593900A (en) * 1989-07-07 1997-01-14 Tryggvason; Karl Immunological methods for the detection of the human type IV collagen α5 chain
WO1991009113A1 (fr) * 1989-12-14 1991-06-27 Regents Of The University Of Minnesota Polypetptide synthetique a activite de collagene de type iv
WO1991008755A1 (fr) * 1989-12-14 1991-06-27 Regents Of The University Of Minnesota Polypeptide presentant une activite d'adherence, de propagation et de motilite de cellules de collagene de type iv
US5424408A (en) * 1990-11-30 1995-06-13 Yale University α-3 chain type IV collagen polynucleotides
US5731192A (en) * 1993-08-27 1998-03-24 Yale University Collagen COL4A6: gene, protein and method of detecting collagen deficiency
WO1996000582A1 (fr) * 1994-06-30 1996-01-11 University Of Kansas Medical Center Utilisation de domaines isoles du collagene de type iv pour modifier les interactions cellulaires et tissulaires

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PRESTAYKO A W ET AL.: "Type IV colagen domains inhibit adhesion and migration of tumor cells and block angiogenesis", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. ANNUAL MEETING, vol. 39, March 1998 (1998-03-01), pages 45, XP002119688 *

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432706B1 (en) 1995-06-30 2002-08-13 University Of Kansas Medical Center Method for inhibiting angiogenesis and tumors with the isolated NC1 α6 chain monomer of type IV collagen
US6498140B1 (en) 1995-06-30 2002-12-24 University Of Kansas Medical Center Use of isolated domains of type IV collagen to modify cell and tissue interactions
US6440729B1 (en) 1995-06-30 2002-08-27 University Of Kansas Medical Center Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen
US6358735B1 (en) 1995-06-30 2002-03-19 University Of Kansas Medical Center Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagen
US6361994B1 (en) 1995-06-30 2002-03-26 University Of Kansas Medical Center Method for inhibiting angiogenesis and tumors with the isolated NC1 α1 chain monomer of type IV collagen
US6962974B1 (en) 1998-06-17 2005-11-08 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
US7387779B2 (en) 1998-06-17 2008-06-17 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
US6759047B1 (en) 1998-06-17 2004-07-06 Beth Israel Deaconess Hospital Corp. Anti-angiogenic proteins and methods of use thereof
US9758551B2 (en) 1999-10-20 2017-09-12 The Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
AU783662B2 (en) * 2000-01-07 2005-11-24 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
JP2003519630A (ja) * 2000-01-07 2003-06-24 ベス イスラエル ディーコネス メディカル センター 抗血管新生タンパク質およびその断片ならびに使用方法
WO2001051523A3 (fr) * 2000-01-07 2002-08-08 Beth Israel Hospital Proteines et fragments de proteines anti-angiogeniques et leurs procede d'utilisation
WO2001051523A2 (fr) * 2000-01-07 2001-07-19 Beth Israel Deaconess Medical Center Proteines et fragments de proteines anti-angiogeniques et leurs procede d'utilisation
WO2001059112A1 (fr) * 2000-02-10 2001-08-16 Zymogenetics, Inc. Peptides intestinaux anti-angiogeniques, zdint5
WO2002012281A3 (fr) * 2000-08-03 2003-07-10 Univ Johns Hopkins Vaccin moleculaire liant un polypeptide chaperon du reticulum endoplasmique a un antigene
US7342002B2 (en) 2000-08-03 2008-03-11 The Johns Hopkins University Molecular vaccine linking an endoplasmic chaperone polypeptide to an antigen
US8007781B2 (en) 2000-08-03 2011-08-30 The Johns Hopkins University Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
WO2002012281A2 (fr) 2000-08-03 2002-02-14 Johns Hopkins University Vaccin moleculaire liant un polypeptide chaperon du reticulum endoplasmique a un antigene
US7175840B2 (en) 2001-01-05 2007-02-13 Viromed Co., Ltd. Compositions for gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof
WO2002083072A3 (fr) * 2001-04-13 2003-04-17 Thompson Boyce Plant Res Methodes et compositions pour medicaments stables a base de plantes transgeniques et leur utilisation comme contraceptifs
WO2002083072A2 (fr) * 2001-04-13 2002-10-24 Boyce Thompson Institute For Plant Research Methodes et compositions pour medicaments stables a base de plantes transgeniques et leur utilisation comme contraceptifs
CN100447155C (zh) * 2001-05-23 2008-12-31 中国科学院上海上海生命科学研究院 具有抑制内皮细胞生长活性的重组人内皮生长抑制蛋白
US9701725B2 (en) 2003-05-05 2017-07-11 The Johns Hopkins University Anti-cancer DNA vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
US9011866B2 (en) 2005-01-06 2015-04-21 The Johns Hopkins University RNA interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by DNA and transfected dendritic cell vaccines
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US20140179612A1 (en) * 2011-08-17 2014-06-26 The Regents Of The University Of Colorado, A Body Corporate Transferrin-Tumstatin Fusion Protein and Methods For Producing and Using the Same
US9290562B2 (en) * 2011-08-17 2016-03-22 The Regents Of The University Of Colorado Transferrin-tumstatin fusion protein and methods for producing and using the same
CN111087477A (zh) * 2020-01-03 2020-05-01 四川大学华西医院 GBM-7S(α1)-NC1(α3)融合蛋白及其制备方法
CN111087477B (zh) * 2020-01-03 2021-10-08 四川大学华西医院 GBM-7S(α1)-NC1(α3)融合蛋白及其制备方法

Also Published As

Publication number Publication date
CA2331332A1 (fr) 1999-12-23
JP2008301823A (ja) 2008-12-18
KR100682666B1 (ko) 2007-02-15
CN1309663A (zh) 2001-08-22
JP2002517999A (ja) 2002-06-25
IL140239A0 (en) 2002-02-10
AU753249B2 (en) 2002-10-10
AU4575599A (en) 2000-01-05
KR20010053018A (ko) 2001-06-25
EP1086129A1 (fr) 2001-03-28
JP2008019271A (ja) 2008-01-31

Similar Documents

Publication Publication Date Title
US7387779B2 (en) Anti-angiogenic proteins and fragments and methods of use thereof
AU753249B2 (en) Anti-angiogenic proteins and methods of use thereof
AU2006200751A1 (en) Anti-Angiogenic Proteins and Fragments and Methods of Use Thereof
US6759047B1 (en) Anti-angiogenic proteins and methods of use thereof
US6962974B1 (en) Anti-angiogenic proteins and fragments and methods of use thereof
US20080167227A1 (en) Anti-angiogenic and anti-tumor properties of matin and other laminin domains
US20050255107A1 (en) Anti-angiogenic proteins and fragments and methods of use thereof
EP1268798B1 (fr) Propriétés anti-angiogéniques de la proteine vascostatin et fragments et variants de celui-ci
AU2001287274B2 (en) Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains
AU2001245994B2 (en) Anti-angiogenic and anti-tumor properties of matin and other laminin domains
EP1719779A2 (fr) Anticorps contre le Matin
US20080167232A1 (en) Anti-angiogenic and anti-tumor properties of vascostatin and other indogen domains
AU2001287274A1 (en) Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains
AU2001245994A1 (en) Anti-angiogenic and anti-tumor properties of matin and other laminin domains

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99808686.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 45755/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 140239

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2331332

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1999928762

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2000 554765

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020007014426

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1999928762

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020007014426

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 45755/99

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1020007014426

Country of ref document: KR